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Idea Analysis was investigated to determine its ability to organize scientific information 
and explain the results of specialists' deliberations in designing new clinical trials. 
Ideas have long been recognized as the engine of creativity. By focusing on the capture 
of ideas from the scientific literature, idea analysis procedures enable the arrangement 
of the inforniation into forms consistent with those developed by subject specialists. The 
most obvious example is the concept structure. Ideas containing a common frequently 
occurring term/phrase can be depicted as a primary node in the concept network. 
Related terms will appear as elements associated with that node. Ideas containing couplets 
of primary nodal terms/phrases can be used to link nodes, thus, completing the paths in 
the network. Using this methodology, information specialists can build and maintain 
knowledge structures for use by students, subject specialists and interested others. 
In contrast with expert systems, idea analysis does not attempt to duplicate thought 
processes performed by experts in a subject. Instead, it focuses on the management of 
ideas and the arrangement of those ideas using organizational models. The application 
of these techniques to the scientific literature dealing with brain tumors and to clinical 
trial protocols developed by subject specialists is illustrative. 
This study showed that, in the brain tumor literature and clinical trial protocols, the idea 
analysis approach was effective in accomplishing the two tasks required: 1. organization 
of complex material into succinct and understandable descriptions--tabular and graphic; 
2. provision of explanations of expert-derived research strategies and/or plans. This 
methodology enhanced identification, extraction, computerization and incorporation of 
ideas into knowledge structures in an efficient and effective manner. 
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Chapter I 
Introduction 
Introduction 
Clinical and laboratory research has led to significant advances in medicine. As 
an example, there has been dramatic improvement in the number of patients with 
childhood acute lymphoblastic leukemia living for five years or longer. In 1960, 10% 
of these patients were alive at five years. Today, the survival rate is 85 % for those with 
low risk acute lymphoblastic leukemia and 70 % for high risk acute lymphoblastic 
leukemia (Hammond, 1989). In recognition of the importance placed on this type of 
advancement, the National Cancer Institute budget for research was $1,979 billion in 
1993 (National Institutes of Health, 1994, pp. 109-111). 
Programs of this magnitude are targets for continuing criticism regarding their 
efficiency and effectiveness. Such programs are developed, evaluated, and performed 
by groups of subject experts. The assumption underlying this process is that, by bringing 
the various levels of expertise and experience to bear on a problem, a consensus can be 
reached in identifying important problems, appropriate approaches for study, and correct 
interpretations of findings. This process of using subject peers to develop, perform, and 
evaluate requires that these individuals have a thorough and complete knowledge of the 
subjects related to the problems of interest. To ensure that this requirement is met, large 
and diverse groups are amassed by federal agencies to provide guidance and consultation 
(Cheson, 1991). 
Critics of such processes claim that the 'committee' approach is inefficient and 
that the problems selected are not the important ones. These individuals claim that the 
task of reaching consensus forces compromises which may prevent original, innovative 
problems from being addressed. Proponents of such processes claim that the committee 
approach is the most pragmatic in dealing with complex and sophisticated problems. 
Further, this technocratic consensus-forming process is not comparable to other 
committee-like functions. Instead, the expert-driven consensus process provides a clear-
cut description of the state of knowledge at any time. Both proponents and opponents 
agree that the essence of the problem is effective information processing. The question 
unresolved in this continuing controversy over large-scale publicly financed research in 
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medicine, as in other fields of science, is, "What is the most effective methodology to 
employ in processing dynamically changing informational data?" 
Problem 
Clinical investigation has been perceived as a form of creative scientific behavior. 
The methodology involved is called clinical trial research. The clinical investigation 
differs from other forms of research in that two equally important objectives are 
considered. The first is the provision of best available care to patients with specific 
disease characteristics. The second is the acquisition of new information which will 
enhance understanding of the disease process and its management. The development of 
this important form of investigation in medical science has required the expertise and 
skill of persons knowledgeable in the particular branch of medicine and in the 
methodology essential to the acquisition of new therapeutic information (Carter, 1985). 
There has been evidence from studies in information science (Bawden, 1986; 
Horowitz & Weiner, 1986b; Le Coadic, 1990), artificial intelligence (Michie & Johnston, 
1985; Rennels, 1986), cognitive science (Johnson-Laird & Wason, 1977; Kasperson, 
1978; Rouse, 1986), and machine learning (Langley, Simon, Bradshaw, & Zytkow, 
1987; Salzberg, 1988) that formal information processing technology may play an 
important role in duplicating the expert's behavior in creative scientific acts and in 
surpassing the expert by 'finding' important new study strategies faster and earlier. 
Also, this methodology is cost effective and does not require additional skilled medical 
experts. 
The problem to be studied deals with the duplication of the results of the human 
expert's creative scientific behavior by using a new information processing algorithm to 
identify, extract, store, retrieve and organize ideas for the development of new clinical 
trial strategies. In addition, assuming that these results can be duplicated by an 
information processing algorithm, the implications of this process need to be considered. 
The algorithm performs two important tasks: 
1. Identification of the ideas involving patient selection, potential 
treatments, and relevant outcome parameters. 
2. Organization of these ideas in the form of a general clinical 
research strategy. 
Ideas are complex, in that they represent a linking by the author of two or more 
terms/phrases. Each linkage presents a thought considered to be relevant by the author-
investigator. Identification and extraction of these ideas involves the establishment of a 
formalized technique involving determination of informational terms and their occurrence 
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as pairs. Once the ideas are available for organization, they can be arranged to raise new 
questions which could be formally studied. The questions and elements making up the 
study process represent a research strategy, where each strategy consists of the essential 
ideas needed to construct the research design and associated procedures used in a clinical 
trial protocoL 
Background 
Is There a Creative Process? 
Advances in medical treatments come from the application of new knowledge 
gained from medical experiments (Jenkins & Hubbard, 1991). One source is results of 
previous clinical studies. Another source is represented by work in the basic sciences. 
As an example of the mutual contribution of information, consider cell kinetics and 
cancer chemotherapy. Laboratory research performed in the early 1970s showed the 
existence of a protein involved in cell transport. That protein was called P-glycoprotein. 
Later work identified the multiple drug resistant (MDR) gene and its expression of 
P-glycoprotein (DeVita, 1991). In 1986, a study was conducted to determine if MDR-l 
expression could predict survival and response in multiple myeloma refractory to 
alky lating agents (Wells et al., 1994). In a 1990s randomized clinical trial of relapsed 
or refractory childhood leukemia, one goal was to see if the MDR gene could determine 
the rate and duration of response (Cornelissen et al., 1994). Interest in this area is now 
moving to ways of overcoming the MDR gene. One example is the opening in 1993 of 
a new clinical trial protocol by the Pediatric Oncology Group. This protocol is entitled 
"Phase II Study of Cyclosporine to Overcome Multiple Drug Resistance to CDDP/DOX 
Chemotherapy in Patients with Progressive or Recurrent Osteosarcoma." One of the 
objectives of this protocol is to "determine the frequency of expression of P-glycoprotein 
in these patients" (Pediatric Oncology Group, 1993). 
In 1985, Seeger et al. studied the association between number of copies of N-myc 
oncogene and outcome in neuroblastoma. Shimada et al. in 1984 investigated 
histopathology as a prognostic factor in neuroblastoma. Look, Hayes, Nitschke, 
McWilliams & Green (1984) reported on cellular DNA content as a predictor of 
outcome. The prognostic importance of serum specific enolase in neuroblastoma was 
studied by Zeltzer et al. (1985). Hann et al. (1985) reported on the prognostic 
importance of serum ferritin in neuroblastoma. Moss et al. (1985) used a method of 
marrow immunocytology to identify tumor contamination in the bone marrow. Results 
from these studies of disease factors that showed prognostic value (i.e., a relationship 
involving factors observed at diagnosis or before initiation of treatment, with post-
treatment disease control and/or survival) and a method to identify disease in the bone 
marrow were incorporated into a Childrens Cancer Group protocol (CCG-3891) 
investigating a new treatment modality, autologous bone marrow transplantation. The 
study opened in 1991. One objective in looking at these prognostic factors was to see 
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if "characterization of the study population by prognostic factors will allow us to define 
new subsets of patients important in designing future studies, and help us to determine 
which patients are being helped by the treatment" (Childrens Cancer Group, 1991). 
Appropriate organization of the clinical and laboratory information leads to subject 
descriptions. While these descriptions can take various forms, a typical display consists 
of a graph of the ideas and the linkages among them. Such displays are called concept 
structures (Edmondson, 1994; Novak, 1984; Preiss, Black, Caron, & Shapcott, 1992; 
Sowa, 1984). 
In realizing a new conceptual display, typically, a subject expert is recruited to 
perform the work. This individual identifies and retrieves the appropriate literature. The 
information from these articles is organized using subjective criteria which to the outsider 
may seem to be mysterious. The result of that process is a new description of the 
literature. This description, in graphic or text form, consists of important terms/phrases 
representing central themes. These themes are interconnected to form a network of ideas 
describing the subject. Surrounding each theme can be the ideas which augment and 
further describe the theme's characteristics and importance. Such thematic clusters are 
called concepts and the linking of the concepts is called a concept graph or network. 
When these concepts deal with diagnosis, treatment and outcome, the conceptual 
structure can be used to form a new clinical trial research strategy. This approach has 
been dramatized in the literature. It is clearly part of the "creative process" applied to 
developing new approaches in medicine (Austin, 1978; Holmes, 1986; Purica, 1988). 
A second approach exists. This approach is more public in process. It involves 
formal, computerized analysis and processing of the scientific materiaL The intent is to 
duplicate the end results of the expert, rather than the methods of organization used. 
There have been attempts to introduce aspects of mystical drama in this setting as well 
(Schank, 1991; Frawley, Piatetsky-Shapiro, & Matheus, 1992). However, for the most 
part, the process has been described in mundane, realistic terms. Descriptors include: 
information management, data processing, indexing, coding, etc. (Chu & O'Brien, 1993; 
Hersh & Greenes, 1990a; Humphrey, 1992; Liston & Howder, 1977; Salton, Buckley, 
& Smith, 1990). 
If the latter approach does duplicate the end results from the "creative activity" 
performed by the expert, there would be a need for new descriptions of cognitive 
activities and their sequelae. There would be evidence to suggest that the creative 
process is not a "light bulb" going off in the scientist's mind but, rather, is a process of 
problem solving that relies on information (Davies, 1989; Davies, 1990; DeVita, 1991) 
and the ability to organize and process information (Findlay & Lumsden, 1988; Garrett, 
1985; Green, Bean, & Snavely, 1984), 
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Approaches in Studying the Creative Process 
Three approaches have been employed in studying the creative process as 
performed by scientific investigators engaged in clinical research. These may be 
summarized by considering the principal study mechanisms and the results of their 
research. The knowledge engineer constructs rule-based scenarios performed by the 
computer (J. S. Bennett, 1985; Boose, 1985; Buchanan et aI., 1983; Davis, Buchanan, 
& Shortliffe, 1984). If successful, the computer will acquire information, analyze it, and 
perform appropriate actions as a consequence. The emphasis is on tracking the behavior 
of the expert, so that the results from the computer will match those from the human. 
The linguist employs a more archeological approach in analyzing the creative 
process in science. This investigator focuses on the text produced by the scientists and 
attempts to discover patterns of language and underlying behavior. The linguistic 
analysis identifies the scientist's use of words, phrases, and text construction (Harris, 
1952; Winograd, 1983). Much of the analysis is based on frequency distributions of the 
word patterns observed. The premise is that, by developing descriptions of these word 
patterns, the cognitive process used in developing the text can be better understood. 
The idea analyst also focuses attention on the end product of the expert's 
actions by analyzing the scientific text (Chen, 1988; Hoffmann, 1980, 1982; J. M. 
Weiner, Stowe, Shirley, & Gilman, 1981). In contrast to the linguist, his emphasis is 
on the specific ideas displayed. These ideas are extracted, computerized, and analyzed 
in constructing concept structures, scholarly reviews, and research strategies (Fuller, 
Gilman, Weiner, Stanley, & Weiner, 1982; G. F. Weiner et aI., 1984; J. M. Weiner, 
Horowitz, & Bauer, 1987; J. M. Weiner, Horowitz, & Latinwo, 1987; J. M. Weiner, 
Shirley, Gilman, Stowe, & Wolf, 1981). The methods employed in the construction of 
these end products of the scientist's activities are not intended to duplicate those used by 
the subject matter expert, since the methodologies are unknown. Instead, the idea analyst 
employs straightforward segregation and clustering procedures in attempting to construct 
the desired products (R. S. Horowitz & Weiner, 1986a, 1986b). 
The Information Explosion and Its Effects on Creativity 
The increasing volume of published literature (Arndt, 1992; Durack, 1978; 
Elliott, 1994; Pincetl, 1990) contributes to the delay in developing new clinical trials by 
providing the scientist with large volumes of information that need to be extracted and 
incorporated in the scientist's knowledge base. 
Table 1 shows the volume of literature in MEDLINE, one of the major 
biomedical databases. 
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Table 1 
Number of Articles Per Year Entered into MEDLINE 
Total 
Year Number of Brain Acute Breast Lung 
Articles In Neoplams Leukemia Neoplasms Neoplasms 
MEDLINE 
1993 377,606 1,806 2,787 3,849 3,119 
1992 375,232 1,777 2,707 3,695 3,106 
1991 374,242 1,679 2,520 3,236 2,882 
1990 375,350 1,811 2,583 3,283 3,142 
1989 369,236 1,663 2,671 3,231 2,913 
According to the National Library of Medicine (NLM), on the average, 30,000 articles 
are added per month. From receipt of a "priority one II journal to the appearance of the 
article in the database takes approximately 30 days. For other journals, the time frame 
ranges from 6 to 12 weeks (Catherine Soehner, National Library of Medicine, February 
7, 1994, personal communications). 
The increasing number of articles has been recognized universally as a significant 
problem in keeping up with the information being distributed. Two methods of reducing 
the number of articles to be looked at have been considered. One involves the use of 
review articles (Mulrow, 1987; Oxman & Guyatt, 1991; Oxman et aI., 1991). The other 
involves meta-analysis (Antman, Lau, Kupelnick, Mosteller, & Chalmers, 1992; Gelber 
& Goldhirsch, 1991; Mann, 1990; Mosteller & Chalmers, 1992; Whitehead & 
Whitehead, 1991). Reviews are prepared by subject experts and provide descriptions of 
the characteristics considered by the involved authors to be important and relevant. They 
don't have to agree and often do not. Meta-analysis involves the formalized pooling of 
the data from different studies, with the view of forming a common set of findings. Both 
methods have limitations based on what items the authors include. The summaries also 
require more expert time in preparation than may be available. 
Information science research has been focused on methods to find and retrieve 
information (Bernier, 1961; Findler, Maini, & Yuen, 1992; Hersh & Greenes, 1990b; 
Lindberg, Humphreys, & McCray, 1993; McKinin, Sievert, Johnson, & Mitchell, 1991; 
P. L. Miller, Barwick, Morrow, Powsner, & Riely, 1988; Pao, 1993). A few systems 
have looked at extracting the information in the article (Hankom & Srinivasan, 1994; 
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Jacobs & Rau, 1990; Schwarz, 1990; Shuldberg, Macpherson, Humphrey, & Corley, 
1993; Szpakowicz, 1990). Other systems are designed to build a reference base of the 
information available. Such reference bases are called knowledge bases. Currently, 
these databases are built by experts, based on information from a variety of sources 
(Bernstein, Siegel, & Goldstein, 1980; Masarie, Miller, & Myers, 1985; Moens, 1992). 
Another technique to organize and improve access to the literature is hypertext. With 
hypertext, links are formed, either by the author or user, between various parts of a 
document in a non-linear fashion. This arrangement allows the user to explore the 
information in documents in a variety of ways which can lead to new discoveries. 
Problems with hypertext include getting lost in the text due to faulty guidance and/or 
linking called 'lost in hyperspace' and difficulties in maintaining or understanding links 
created by the author (Cimino, Elkin, & Barnett, 1992; Conklin, 1987). 
One system, Idea Analysis, combines two important information management 
requirements. The first is knowledge representation involving the identification, 
extraction, and organization of information in the form of ideas found in scientific 
literature. The second is rule-based information processing which takes the knowledge 
elements and utilizes them in forming new descriptions of the subject. This system is 
intended to duplicate the results produced by subject matter experts engaged in clinical 
trial research (G. F. Weiner et aI., 1984; J. M. Weiner, Horowitz, & Latinwo, 1987; 
J. M. Weiner, Shirley, et aI., 1981; J. M. Weiner, Stowe, Shirley, & Gilman, 1981). 
Preliminary studies of this method have been performed by investigators at the 
Information Systems Research Program, University of Southern California School of 
Medicine (USC) (Stowe et aI., 1983; G. F. Weiner et aI., 1984). In those investigations, 
the idea set used was restricted to those displayed as numerical relationships in the form 
of tables and/or graphs. Those investigators hypothesized that this form of filtering 
yielded a necessary and sufficient subset in building concept structures. They used that 
idea set to develop descriptions of subjects (1. M. Weiner & Horowitz, 1990a, 1990b, 
1991a, 1991b, 1991c; J. M. Weiner, Malogolowkin, & Horowitz, 1992a, 1992b, 1992c, 
1993). 
Study Purpose 
This dissertation describes the investigation of an information processing approach 
intended to duplicate the research strategies developed by experts. As in the USC 
studies, the ideas employed will be restricted to the set derived from numerical 
relationship displays. These ideas were organized using a new algorithm to form 
descriptions of clinical trial research strategies. These strategies, in turn, were compared 
with those developed by the subject experts. 
This study was designed to determine the effectiveness of the new algorithm in 
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explaining and describing the results obtained by the specialist. The question addressed 
was, "Does model-specified organization of ideas from the scientific literature match, in 
informational content, the strategic information provided in clinical trial protocols?" 
Significance 
The significance of this study will be in validating the use of ideabases to 
duplicate the expert's ability to design clinical trial strategies. A second important 
outcome will be in providing the investigator with new tools to enhance and expedite the 
performance of cognitive creative acts in clinical trial investigation. 
Limitations 
There are a number of limitations to the approach envisioned. First, the 
comparison made involved ideas from the literature versus those from clinical trial 
protocols. As such, there is the possibility that the data sets are not comparable, in that 
the literature provides original findings and the protocols provide expert-filtered and 
summarized findings. The database of clinical trial protocols is selected by subject 
specialists. The source used in this study was the Physicians Desk Query (PDQ) system 
of the National Cancer Institute (NCI). PDQ maintains records on all open and closed 
protocols approved for inclusion by its editorial board. In general, protocols from 
federally funded research and from other selected researchers are included. This 
database was used to select clinical trials studying treatments for patients with brain 
tumors. 
Secondly, the subject specialist process and the computer algorithm have different 
supporting databases. Investigators designing clinical trial protocols have access to all 
of the world's literature including laboratory, pre-clinical and clinical information. They 
also have access to pre-published information via contacts with colleagues. The 
ideabases are limited to clinical literature and only to those articles containing numeric 
displays. 
Thirdly, this analysis will be limited to clinical trials of treatments for patients 
with brain tumors. While there is no a priori reason to expect clinical trials of brain 
tumors to be different from those found in other diseases, that premise is assumed rather 
than tested in this study. If the methodology is effective, extrapolation to other disease 
subjects should be straightforward. 
Summary 
Randomized clinical trials are critical to the advancement of medicine. Methods 
are needed that reproduce the results of the creative process used by scientists. Ideally, 
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such methods should reduce the time and effort needed to design protocols. Since the 
number of published scientific articles has been exponentially increasing over the past 
years, the methods employed in bringing new information to the clinical trial design 
capability should facilitate continuous integration of new with existing information. A 
methodology called Idea Analysis will be investigated to determine its ability to 
accomplish the organization of the information, such that the results of the specialists' 
deliberations in designing new clinical trials can be explained. If this is accomplished, 
the procedure satisfies the requirements needed, in that it can manage large volumes of 
informational data and can integrate new with existing information. 
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Chapter II 
Review of the Literature 
Literature Review 
Several areas of information processing will be considered with respect to their 
relationships with the clinical trial process. The questions of concern are illustrated in 
Figure I. 
This simplified concept map shows two systems of interest which are widely 
acknowledged components of information processing. Creativity and a methodology 
which might be of value in that process are linked to information processing. This link, 
however, is not well established and is denoted by the question mark. Similarly, the link 
between clinical trials and information processing is present but in a different context 
than that considered here. That is, the question of creating clinical trial strategies 
through appropriate information processing algorithms is one which has not been 
demonstrated clearly in the literature. Again, the uncertainty is denoted by the question 
mark. Finally, is there a link between creativity and clinical trials? Is the formation of 
a clinical trial strategy a creative process? 
Clinical Trials 
History of Clinical Trials 
The importance of clinical trials to therapeutic medicine cannot be overstated. 
They are considered "a key research activity with a potential to improve the quality of 
health care and control costs through careful comparisons of alternative treatments" 
(N ational Institutes of Health, 1975). Clinical trials are not a recent medical innovation. 
One of the first is described in the Book of Daniel, Chapter 1, verses 12-15 (Lilienfeld, 
1982). Additional references to evaluating medical treatment can be found in the records 
of ancient Greece and Rome (Bull, 1959). 
The earliest reported formal clinical trial was conducted in 1747 when James 
Lind, a ship's surgeon, studied prevention and treatment of scurvy. He took 12 sailors 
and divided them into six groups of two sailors each. Each group was given a different 
type of supplement: cider, elixir vitriol, vinegar, sea water, a herb mixture and 
oranges/lemons. The outcome is the well-known fact that the citrus fruits did prevent 
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Figure 1 
Concept Map of Areas of Interest in Considering the Question: Is the development 
of a clinical trial an example of the creative process? 
? GREATIVV..--------
i 
? 
. 
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and successfully treat scurvy (Bull, 1959; Bulpitt, 1983, pp. 5-11). One of the first 
multicenter clinical trials was performed by the Medical Research Council in 1946 to test 
the efficacy of streptomycin in pulmonary tuberculosis (Doll, 1982; Meinert & Tonascia, 
1986, pp. 2-17). The model used in that trial is basically unchanged even today. 
In the United States, clinical trial research can be traced back to 1891 and the 
Laboratory of Hygiene which became part of the Public Health Service (PHS) in 1912. 
In 1918, the first monetary award was made by the PHS to an outside institution to 
support the U.S. Army's work in fighting venereal disease. In 1930, by an Act of 
Congress, the Laboratory became the National Institutes of Health (NIH) and moved to 
Bethesda, Maryland. In 1937, the National Cancer Institute (NCI) was founded as part 
of NIH (Hawkins, 1988). The National Institutes of Health now number thirteen and are 
a major source of research funds for clinical trials (National Institutes of Health, 1994). 
The institutes have established standards for performance in clinical trial investigation in 
the United States and throughout the world. 
Efficacy of Clinical Trials 
In order to effectively study many diseases, medical research institutions have had 
to pool their resources and patient experiences to obtain data in a timely fashion. These 
cooperative clinical trial groups exist throughout the world and are the principal source 
of information regarding therapy (Office Technology Assessment, 1983; Pocock, 1983, 
pp. 19-21; Simon, 1991). The outcome of their trials greatly impacts on the practice of 
medicine. One example of this is the five year survival rate for childhood acute 
lymphoblastic leukemia. This rate has changed from 10-20% in the early 1960s to 85 % 
today (Hammond, 1989). The results from two large cardiovascular clinical trials [The 
Multiple Risk Factor Intervention Trial (MRFIT) and the Lipid Research Clinics 
Coronary Primary Prevention Trial (LRC)] have shown reductions in risk for fatal and 
nonfatal coronary events. For MRFIT, the results were a 26% reduction and, for LCR, 
a 36% reduction (Strandness, 1991). Ford, Kaluzny, & Sondik (1990) reported on the 
sharp increase in patients receiving segmental mastectomy after the publication of the 
results of a clinical trial performed by the National Surgical Adjuvant Breast and Bowel 
Project. 
Cost of Clinical Trials 
In addition to survival rates, the efficacy of clinical trials can be seen in costs of 
medical care. Detsky (1989) reported that the "cost-effectiveness for performing the 
trials ranged from a low of $2 to $3 per life-year saved for a trial of aspirin in unstable 
angina to a high of $396 to $685 per life-year saved for the randomized trial portion of 
the Coronary Artery Surgery Study." Plum (1985) estimated that, if all the patients 
enrolled in the Extracranial-Intracranial Bypass Trial had been operated on, the cost 
would have been $11 million dollars, whereas the cost of the clinical trial was $9 million 
dollars, a $2 million dollar savings. Boissel (1989) calculated that, if the clinical trial 
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of streptokinase was as large as two other clinical trials, 60,000 lives in France would 
have been saved. 
The cost of conducting clinical trials is high. Detsky (1989) reports the following 
costs of several major clinical trials: 
Lipid Research Clinics Trial $150 million 
Multiple Risk Factor Intervention Trial 110 million 
Coronary Artery Surgery Study 5 million 
Intravenous Streptokinase in Acute 
Myocardial Infarction Trial 3.25 million 
Total Parenteral Nutrition V A 2.6 million 
Canadian Aspirin In Unstable Angina Trial 1 million 
, 
Propranolol in Esophageal Varices Trial 78 thousand 
The overall budget for the National Heart, Lung, and Blood Institute (NHLBI) 
was $232.6 million in 1972 and $965.3 million in 1988. Of these amounts, respectively, 
$12.6 million in 1972 and $73.1 million in 1988 were designated for clinical trials 
(Friedewald, 1990). In 1992, the National Cancer Institute budget was $1,947,571,000, 
with $1,609,739,000 used for clinical research and $390,000,000 of the clinical research 
budget going to support cooperative clinical trial groups (National Cancer Institute [NCI] , 
1992, pp. 56, 130-131). 
The Clinical Trial Process 
Clinical trials are used when standard treatments fail to cure or control disease. 
The new information provided by the clinical trial mechanism is intended to improve the 
quality of care and treatment outcomes. The development of clinical trials is a 
sophisticated process involving the contributions of many different investigators, each 
specializing in different diagnostic and therapeutic modalities. These investigators bring 
to the planning process their individual bodies of knowledge and, through group 
interaction, evolve a strategy for a therapeutic approach, a treatment plan, and a design 
for a clinical trial (Carter, 1985; Cheson, 1991; Pocock, 1983, pp. 1-21). This 
development process may require months to years of discussion and information 
exchange. The time is spent overcoming sources of confusion and obfuscation. The 
various disciplines represented contribute to the developmental time by describing 
commonly accepted concepts using different languages and by masking concepts 
intuitively evident to one discipline but not to all. This process is a modern version of 
the 'Tower of Babel' effect (Mikhailov, Chernyi, & Giliarevskii, 1984, pp. 25-26). 
The details of a therapeutic plan include characteristics defining: 
.. patients eligible for the trial; 
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• dose, route, schedule, and modifications of each systemic 
treatment component; 
• monitoring of the patients throughout the trial; 
• monitoring of the performance of the trial; 
• information on how the study will be analyzed; and the 
interpretation of the results (Meinert & Tonascia, 1986; Pocock, 
1983). 
Obstacles to Clinical Trial Design 
A primary problem facing researchers is the sheer volume of literature to be 
considered. The ten thousand scientific and technical journals now published increase 
by six to seven per cent a year (de Solla Price, 1981). This increase in the literature is 
reflected in a policy change by the National Library of Medicine from a monthly update 
of the MEDLINE database to a semi-monthly update schedule ("MEDLINE moving," 
1988). Gabrieli, Speth and Casiraghi (1985) stated that a practitioner should read 657 
articles per day, including Saturday and Sunday, to stay current. Most physicians spend 
a few hours a day reading and have a set time for reviewing journals (H. J. Bennett, 
1992; Manning & DeBakey, pp. 31-56). Many books and articles have been written on 
how to keep up with the literature (Gehlbach, 1993; Haynes et al., 1986a, 1986b, 1986c, 
1986d, 1986e, 1986f; Riegelman, 1981). 
In addition to volume, there is the problem of an increasing number of journals 
in specialty areas (Datta, 1987; Sengupta & Wyatt, 1987; Todd, 1967). Related to this 
problem is the one of identifying the journals where the information may be found. 
Depending on the target group, the authors of an article may publish their results in 
general medical journals, such as the New England Journal of Medicine; general subject 
journals, such as Cancer; or in a discipline specific journal such as Gynecological 
Oncology (Dunn, 1981; J. M. Weiner, Shirley, et al., 1981). This dispersal of the 
information requires researchers to spend even more time and money locating all 
pertinent information. 
Other sources of information for researchers include: the invisible college, 
textbooks, scientific meetings, and workshops (Crane, 1969; Manning & DeBakey, pp. 
81-100; Osiobe, 1985; A. D. Weinberg, Ullian, Richards, & Cooper, 1981). For 
researchers in cooperative groups, the unpublished data of recently completed studies and 
preliminary analyses of current trials provide additional information (Malogolowkin et 
aI., 1989). 
A second obstacle in clinical trial design is obtaining consensus among the experts 
regarding what information should be used (Bernstein et al., 1980; Giuse et al., 1993; 
Rossi-Mori & Steve, 1985, Shaw & Gaines, 1989). One aspect to be considered is the 
need to separate the ideas from the data. Many ideas may be rejected because the author 
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or institution is not well known, the methodology appears flawed, or there is some other 
unspecified bias (Peters & Ceci, 1982; Suarez & Lemoine, 1986). The rejection of these 
ideas contributes to the delay in developing clinical trial strategies. 
Cognitive Processes and New Clinical Trial Research Strategies 
Creative Process 
Is creativity really the "A hal" factor, where out of nowhere a person sees the 
solution to a problem, or writes a poem, or creates a work of art, or has some formal 
process preceded the insight? (Weisberg, 1986, pp. 89-107) 
Creativity is considered to be highly individualistic. Some believe that chance 
plays an important role in accomplishing a creative act. Others believe that the creative 
person is more effective in utilizing available information (Bawden, 1986; Findlay & 
Lumsden, 1988; Rouse, 1986). Creativity also has been defined as a combination of 
chance and effective information processing (Beveridge, 1980; Rawlinson, 1974; Stein, 
1974, pp. 13-39; Taylor & Barron, 1963; Weisberg, 1986). The variety of definitions 
illustrates the lack of agreement, but these definitions do have elements in common. 
Formal techniques for stimulating creative activity include Brainstorming (Rawlinson, 
1974), Synetics (Gordon, 1961), Morphological Analysis (Zwicky, 1969) and Lateral 
Thinking (de Bono, 1970). These techniques all include the common theme of 
organization of existing information with intent to display the material in different ways. 
The techniques assume an efficient analytic process to sort, collate, and display the 
various informational elements. Implicit in the descriptions of the methods is the 
existence of conceptual or idea files containing the 'data' which are to be processed. 
Guilford (1967) described creativity as novel thinking. He stated that "novel 
thinking means that retrieved information is to be used in a new form or in new 
connections.... A theory learned in certain connections is tom out of the context in 
which it was learned for use in some new context" (p. 100). 
Weisberg (1986), in reviewing the work of Watson and Crick on the structure of 
DNA and Darwin's work on natural selection, showed that their results did not corne 
from the unknown but rather "the theorist involved began with ideas that were readily 
available in the scientific community. These ideas were then modified to make them 
relevant to the specific problems they were trying to solve" (pp. 105-106). This 
description suggests that creativity is a process of using known information in a new 
format. 
McConathy (1990) reviewed several theories of creativity and summarized that 
"a theory of creativity should account for several attributes: a time sequence of slow 
laborious work with sudden, apparent "gaps" and subsequent insights; individual 
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differences; and a generalized form of creativity (problem solving) not unique to fine arts 
or sciences" (p. 12). One of the theories reviewed was Mednick's associative theory 
which links creativity with the ability to combine elements in new ways. A second 
theory reviewed was Simon's information processing theory which stated that problem 
solving is done by carrying out several elementary processes in a hierarchical fashion. 
Two of these steps, incubation and inspiration were explained as familiarization and 
selective forgetting. Familiarization is the process of continually gathering information 
which is stored in long term memory and is recalled over time to solve the problem. 
Selective forgetting or inspiration is the time when attention is switched back to a 
previous problem and the solution is rapidly found. The reason for the rapid solution is 
that enough information has been gathered and stored in memory. 
Arieti (1976) reported on several theories of creativity. The first was Osborn's 
seven stages of the creative process. These were: 
1. Orientation-pointing up the problem; 
2. Preparation-gathering pertinent data; 
3. Analysis-breaking down the relevant material; 
4. Ideation-piling up alternatives by way of ideas; 
5. Incubation-"letting up," to invite illumination; 
6. Synthesis-putting the pieces together; 
7. Evaluation-judging the resulting ideas. 
A second is from Joseph Wallas, wherein the creative process involved: 
1. Preparation; 
2. Incubation; 
3. Illumination; 
4. Verification. 
A third is from Joseph Rossman. That theory of creativity involved: 
1. Observation of a need or difficulty; 
17 
2. Analysis of the need; 
3. A survey of all available infonnation; 
4. A fonnulation of all objective solutions; 
5. A critical analysis of these solutions for their advantages 
and disadvantages; 
6. The birth of the new idea-the invention; 
7. Experimentation to test out the most promising solution, 
and the selection and perfection of the final embodiment by 
some or all of the previous steps. 
Boxenbaum (1991) indicated there are six stages of creativity: interest, 
preparation, incubation, illumination, verification, and exploitation. 
Noy (1978) indicated that the characteristics of the creative scientist were his 
imagination, originality, and the ability to combine existing categories into a new, unified 
scheme. 
If the creative idea comes from the combination of familiar ideas, then Richman's 
treatise may help to explain the process. Richman (1987) described the concept of 
combining ideas. He wrote, a genius creates new ideas "by combining ideas that have 
never been combined before to create new ideas distinct from the originals" (p. 76). Idea 
combining is not just word combinations but also combinations of procedures. A classic 
example is the application by Henry J. Ford of the assembly line to car manufacturing. 
The prototype process was the assembly line used in meat packing. Another example of 
combining ideas is the extraction of ideas from one discipline and the combination of 
these with ideas from another discipline. The result may be the creation of new insights 
and new approaches. Idea combining is postulated to have led Einstein to his theory of 
relativity. Freud is believed to have combined his clinical observations with the ideas 
of Sophocles given in Oedipus Rex. The strong message penneating the creativity 
literature is that without existing ideas there would be no new ideas. 
Artificial Intelligence 
The major portion of the research in medical artificial intelligence has been in 
diagnostic systems such as MYCIN, INTERNIST and CASNET (R. A. Miller, Pople, 
& Myers, 1982; Shortliffe et al., 1975; Weiss, Kulikowski, Amarel, & Safir, 1978). 
These programs are comprised of a series of If/Then rules that guide the user to possible 
diagnoses and treatments. These systems rely on knowledge bases that were built by 
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extracting the knowledge of experts. 
Programs that offer critiques are a second type of artificial intelligence 
application. These programs evaluate the physician's treatment plan and provide 
additional suggestions or point out potential errors. Programs of this type include 
ATTENDING and ROUNDSMAN (P. L. Miller, 1983; Rennels, 1986). ATTENDING 
evaluates the plans based on a knowledge base of drug reactions, given certain medical 
conditions. ROUNDSMAN compares the plan against results of published clinical trials. 
The ONCOCIN program developed at Stanford University aids the physician in 
complying with the treatment protocol. By combining the data in the knowledge base 
which contains the details of the protocol with newly entered specific patient data, advice 
and explanations can be generated. These are used by the physician to provide better 
patient management (Musen, Rohn, Fagan, & Shortliffe, 1986). 
In contrast to the above, NEWCHEM is a prototype for the development of new 
oncology therapies. The program was built using a knowledge base of molecular and 
cellular biology and drug interactions. Using mathematical models and specific rules 
about drug interactions, potential protocols can be developed (Ardizzone et al., 1988). 
With the exception of NEWCHEM, artificial intelligence research has focused on 
how to treat the patient with currently known procedures. There has been little attention 
paid to the act of creating new treatment strategies. 
Information Retrieval-Content Description 
Emphasis continues on finding the optimum procedure in describing the contents 
of a document. Two approaches remain popular. The first is indexing. The second is 
semantic relationships. 
As an example of newer indexing approaches, the American Petroleum Institute 
has developed an expert system for machine-aided indexing (Martinez, Lucey, & Linder, 
1987). The focus of the system is to select text fragments from the abstracts. The 
selected fragments are then compared with the knowledge base. When a match occurs 
and other conditions are met, the appropriate index term is selected from the thesaurus. 
A second example is the Indexing Aid System. This is being developed at the National 
Library of Medicine (Humphrey, 1992). The system uses a series of frames to build the 
data record for an article. Neither of these systems is designed to improve the 
know ledge representation of the article but, rather, to ensure consistency in how indexing 
rules are applied. 
A different form of content description involves the use of semantic relationships. 
For example, P. L. Miller et al. (1988) investigated the use of semantic relationships to 
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improve retrieval. The system attempts to characterize each paper in the database by a 
semantic network which represents the concepts discussed and their interrelationships. 
A similar project is the MedSORT at Carnegie-Mellon University (Carbonell, Evans, 
Scott, & Thomason, 1986). Both of these systems attempt to improve the representation 
of the article and, in that way, enhance retrieval. 
Inteifaces with Natural Languages 
Other approaches for improved information retrieval are the interface between the 
user and the system. These include PAPERCHASE (G. L. Horowitz & Bleich, 1981), 
which translates the user's input to the correct MeSH terms; CANSEARCH (Pollitt, 
1987), which leads the user through a series of menus in order to generate the 
appropriate search strategy; and the increased number of full text databases that can be 
searched using natural language (Collen & Flagle, 1985). 
A few studies have suggested a different approach to the problem of describing 
the actual information contained in a document (Chen, 1988; Hoffmann, 1980, 1982; J. 
M. Weiner, Stowe, et aI., 1981). These procedures attempt to identify and extract ideas 
rather than keywords or subject headings. 
Intelligent Agents 
One new way to deal with the increase in information and an increasing number 
of databases and information systems has been the development of intelligent agents. 
These agents are computer programs and interfaces which are programmed to act either 
as filters of incoming information or information agents that can be programmed to 
search selected databases to retrieve information that meets the criteria (Maes, 1994; 
McCleary, 1994; Roesler & Hawkins, 1994). 
Natural Language Processing-Hypertext 
One solution proposed to increase access to information is hypertext. This 
process has been described as "unrestricted structuring of information in an information 
space and its flexible access. Its basis is representation of the information space by a 
graph consisting of nodes containing individual pieces of information, and links between 
them." (Maurer & Tomek, 1990, p. 201). Davenport (1990) describes hypertext as a 
"generic label for a cluster of technologies (for input, assembly, access, storage and 
retrieval) which handle material, static or dynamic, in any medium, fixed or temporaL 
Its basic premise is freedom of movement inside and across text, defined as anything 
which has an author, or an owner, in a hypertext system" (p. 176). Hypertext is seen 
as a way to utilize the nonlinear structure of information which is not possible with 
printed documents or current bibliographic systems (Carlson, 1990; Conklin, 1987; 
Maurer & Tomek, 1990; Salminen & Watters, 1992). 
One reason for the interest in hypertext has been the information explosion which 
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has been particularly noticeable in medicine (Arndt, 1992; Durack, 1978; Elliott, 1994). 
However, the information explosion is not a new problem. In 1945, the Atlantic Monthly 
contained an article by Bush which discussed the outmoded methods used to disseminate 
knowledge and how new technology would worsen the problem by increasing the growth 
rate of new scholarly information. He also proposed a solution in a machine called 
"Memex" which used microfilm for information storage and mechanical methods for 
retrieval. In this system, users would retrieve one document and, based on links in that 
document, could retrieve others. The user also could build his own links to form a 
unique retrieval system. 
In 1963, Engelbart published aXmodelhat would use the computer to assist in the 
manipulation of symbols to represent intellectual concepts. In 1968, Engelbart and 
English described the implementation of the model called NS which allowed for the 
retrieval and storage of structured documents and provided the ability to link statements 
between documents. 
Hypertext was coined by Ted Nelson in 1967 and demonstrated in Xanadu, a 
system for the storage and retrieval of text. The long range goal was to have the world's 
literature online with ever expanding links to provide new pathways to the material. 
Today's hypertext systems allow users to browse databases of large amounts of 
text and graphics. These databases can represent many documents. A series of links 
connect the fragments. Unlike books and other printed material which require a user to 
follow a linear path through the text, hypertext allows for the nonlinear use of text. The 
central point to hypertext is the link. These links have several functions: connect a 
reference to the document; connect comments to the text referenced; provide 
organizational information; connect successive sections of text; connect figures to 
discussion in the text (Conklin, 1987). Depending on how these links are constructed, 
the system provides the user with a way to explore ideas by going backward and forward 
through the text, allowing new patterns of information to appear or even moving text to 
different locations by supplying new links. In many ways, the hypertext system 
automates the process of using index cards to record bits of information and then 
rearranging the cards in a variety of ways. 
Along with the power to connect vast amounts of information come some serious 
drawbacks. One of the most serious is being 'lost in hypertext' (Nielsen, 1990). Several 
solutions to the 'lost in space' problem have been suggested. Rada and You (1992) 
proposed navigational aids. One example was a document outline which provided 
information about the structure and meaning of the document. Nielsen (1990) suggested 
overview diagrams that provided users with information regarding location in the global 
space and the local node. Another feature of hypertext is a foot path to tell users where 
they were and what previous nodes were encountered. This device would prevent the 
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user from repeating steps. 
Conklin (1987) described the problem of cognitive overhead and disorientation. 
This problem is similar to the 'lost in space' one, in that the user must expend significant 
effort to maintain perspective as to his/her present location in the database. Other 
problems described include: author links to irrelevant information; missing links (Cimino 
et al., 1992); and slanted views caused by the person creating the links (Doland, 1989). 
Cimino et al. (1992) suggested the use of a hyperdocument. This would provide 
"an alternative model... in which text segments are linked to the concepts which they 
contain and the concepts are linked to each other in a semantic network called the 
'Concept Space.' The concepts and semantic links attempt to approximate potential 
topics of interest, allowing the reader to browse the hyperdocument in an individualized 
manner, rather than in an author-designated one" (p. 238). 
Concept Mapping 
One way to support scientific creatIvIty is to use methods that organize 
information so that the relationships involving the ideas can be seen. One system for 
accomplishing this is the use of concept maps. Novak and Gowin (1984) described 
concept mapping as "a way to help students and educators see the meanings of learning 
materials" (p. 1). They contended that knowledge was not discovered but, rather, 
constructed. This contention fits into many theories of creativity, in particular those that 
indicate new ideas come from rearranging known information. The philosophical basis 
is that ideas make concepts and propositions composed of concepts. In Novak and 
Gowin's view, these are the central elements in the structure of knowledge and the 
construction of meaning (p. 7). The concept maps are designed to show the relationships 
between concepts through the use of propositions which are defined as "two or more 
concept labels linked by words in a semantic unit" (p. 15). One advantage to the use of 
concept maps is that they allow for new information to be assimilated as it is found. The 
maps are somewhat hierarchically arranged, with the concept of interest at the top and 
the related concepts below. They also can be rearranged so that one of the subordinated 
concepts can be moved to the top and expanded. Another advantage of using concept 
maps is that presumably unconnected concepts can be perceived as actually related. This 
rearranging of information is the creative process in action. Used in the educational 
setting, concept maps can show how one person sees the relationships between concepts. 
This information can be shared with others. These maps also show missing linkages that 
a teacher can use as a starting point for new learning. Novak and Gowin found that the 
maps drawn by students are effective in showing misconceptions-linkages between two 
concepts that are clearly false or a linkage that misses a key idea relating two or more 
concepts (p. 20). Although the authors focused their research in the field of education, 
the use of concept maps also applies to scientists. By forming maps of known ideas, the 
relationships can help others understand and duplicate the scientists' activities. 
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Wood (1992) described the use of concept maps developed by an expert as the 
basis in developing a knowledge base for nursing students which dealt with acquired 
immune deficiency sydnrome (AIDS). "The knowledge base is organized according to 
the framework of this expert-derived concept map, and the student learner traverses the 
knowledge base from one subconcept to another by clicking on the subconcept of interest. 
Simultaneously, the portion of the concept map under consideration is represented at the 
top of each screen. Thus, concept maps are used for the organizational framework of 
the knowledge base, both graphically and logically, as well as for providing the 
directional relationship links for traveling through the software environment" (p. 25). 
The authors found that using concept maps made it easier to discard old knowledge and 
incorporate new knowledge with minimal programming effort. Use of concept maps also 
promoted meaningful learning, that is, learning which provided for connections between 
the learned material and prior knowledge. This allowed the learner to transfer the 
learned material to a different context. Another advantage of the concept maps was that, 
instead of receiving new information as thousands of bits of information, students could 
begin learning with an organized framework. This framework could be used to 
categorize the new information as it was received. 
Wood (1992) conducted a study to see if the use of a concept map as the 
knowledge base about AIDS facilitated student learning. The study compared the post-
test knowledge of a convenience sample of nursing students who were randomly assigned 
to either a control computer program or the computer program based on concept maps. 
The experimental program showed a concept map on the screen and had a 'TO MAP' 
button which provided an anchor as the students explored the knowledge base. On the 
post-test scores, students using the concept maps showed significantly better scores on 
18 of 31 items. The author hypothesized that the concept maps facilitated learning, as 
it "reinforces the way knowledge is organized and interrelated in the human mind" (p. 
33). 
Doyle (1961) discussed the use of semantic maps as a way to handle the most 
widespread technical problems. The semantic maps were drawn as having a central 
concept. Subsequent terms were assumed to be related to that central concept. 
Searching for information could be done using any available node. This method allowed 
for a quick scan of content in the form of semantically related terms. The process was 
purported to be faster than scanning abstracts. 
According to Liu & Wen (1994), there are three popular definitions of concepts. 
One has been called the classical view. This definition suggests that concepts share 
common properties that are necessary to define it. A second definition considers 
concepts from a probabilistic view. Here concepts can be represented in terms of 
properties that are characteristic or probable of class members. The third view is one 
called exemplar. In this definition, concepts are categories which may be represented 
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by individual exemplars. Assignment of a new term to a category is determined by 
whether the term is significantly similar to one or more known categories. 
There have been numerous computer applications attempting to build and use 
concept structures. The feasibility of computerized approaches stems from the fact that 
the major function associated with conceptualization is categorization. One computer 
system designed to accomplish this categorization and subsequent organization is called 
COBWEB. This approach uses attribute-value pairs. The attributes are used to cluster 
and classify. COBWEB organizes its conceptual knowledge into a tree hierarchy with 
nodes partially ordered by generality. 
Another system, UNIMEM, organizes knowledge into a concept hierarchy which 
sorts new terms and modifies the hierarchy in the process. One term can be stored with 
multiple nodes. Nodes can be indexed by more than one attribute value from a parent 
node. 
A third approach is the Self-Generated Neural Networks (SGNN). This approach 
uses an algorithm to update its rules and develops well structured hierarchies. 
Sowa and Way (1986) developed a parser that applies grammatical rules to 
generate a parse tree showing the syntactic structure. From this came a semantic 
interpreter that generates conceptual graphs to represent the meaning of the sentence. 
To understand, a user employs four types of knowledge: 1) lexical, which provides 
information about word forms; 2) syntactic, which provides information about word and 
phrase categories; 3) semantic, which provides word definitions, constraints on using 
words, and background information about expectations; and 4) episodic, which provides 
assertions about particular things and events. 
Gomez and Segami (1989) suggested that concepts can be built from the logical 
form of sentences. Integration of concepts is basically a classification task. Sometimes 
the classification of a new concept will cause concepts currently stored in memory to be 
reclassified. Through the use of algorithms, the authors have been able to begin to 
automate the cognitive activities that allow for the integration of new concepts, update 
old concepts and organize long term memory. 
They described the use of the schema in processing information to find and form 
concept descriptions. The schema is a primary method in artificial intelligence for 
understanding information. Schemas can be built by using formation rules which are 
developed for different logical structures. Once this is done, long term memory can be 
searched to see if the concepts (schema) have already been built. This process is called 
concept recognition. If no match is found, the unrecognized concepts are classified and 
the schema expanded. The new schema is stored. This method is considered a model 
24 
of comprehension consisting of concept (schema) formation, concept (schema) 
recognition and concept (schema) integration. The integration of concepts actually 
becomes a classification task. Long term memory is represented as a frame structure and 
the frames are linked by membership definitions. 
Information Extraction 
Shuldberg et al. (1993) described the EDS TemplateFilter System which is 
designed to filter volumes of information and to extract selected pieces of data from 
computer industry journals. The resulting data are stored in tables designed to offer 
comparisons of equipment or software. The data to be extracted are identified and the 
software searches the articles for the desired items. 
Hankom and Srinivasan (1994) described the system EMPIRICIST. It contains 
empirical knowledge believed to be critical in practice and teaching. The representation 
of information in EMPIRICIST is closely related to actual text structure. The system 
uses terms in relationship form to characterize the material stored. 
SCISOR (System for Conceptual Information Summarization, Organization and 
Retrieval) is designed to read short articles from online systems and extract information 
from the articles. A conceptual framework which facilitates retrieval by users is used 
to store the information extracted (Rau, Jacobs & Zernik, 1989). 
The system is a series of programs and uses a variety of parsing techniques and 
natural language analysis of free text. A top down conceptual analysis and a bottom up 
linguistic analysis illustrate two of the methods used. The combination allows for in-
depth analysis when certain grammatical and lexical knowledge is known and a more 
superficial analysis when faced with unknown information. Currently, the majority of 
the lexical and conceptual knowledge in the SCISOR system is hand coded, although the 
system is becoming more automatic. Input into the system is natural language text and 
the output is a data structure or table. The text uses morphology, syntax, 
semantics/conceptual, semantics/lexical, and context information to determine the 
meaning of text. The final step is the production of a text that provides the users with 
a concise summary. 
Hersh and Greenes (1990b) described SAPHlRE, an information retrieval system 
featuring concept matching. SAPHlRE is a new program to test techniques in automated 
information retrieval in the biomedical domain. Its main feature is a concept-finding 
algorithm to process free text into canonical concepts. It converts natural language by 
use of automatic indexing based on probabilistic and linguistic methods. 
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Summary 
Of the various procedures and approaches employed by information scientists, the 
one which offers the most straightforward path connecting the ideas presented in the 
literature with the development of new clinical trials is the algorithm introduced by the 
investigators at USC (J. M. Weiner, Horowitz, & Latinwo, 1987). This methodology 
(briefly described in Chapter One and in detail in Chapter Three) provides the only 
procedures which allow a direct comparison of the results of the creative process 
employed by the subject expert with the results of an information processing procedure. 
If this idea analysis algorithm is effective, the time required to develop new 
therapeutic strategies could be reduced in major ways. Foremost would be the ability 
to minimize the time to recognition of plausible strategies. These would be prepared by 
the algorithm and presented to the investigative team. The selection of one or more 
strategies to study would be based on feasibility and economic issues rather than on 
scientific ones, since the latter had been considered in forming the strategies. Once a 
treatment strategy had been selected, other computer supported programs could be used 
to create the rest of the protocol. 
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Chapter III 
Methodology 
Introduction 
Idea analysis represents a new approach to the analysis of the scientific literature 
and to the use of the information obtained. An important difference, when compared 
with existing online information systems, is the emphasis placed on the use of the 
information. The end result of the process is a description of existing knowledge using 
graphic or tabular displays of the concepts studied in a particular subject. This 
organization of ideas to form representations of concept structures is a major 
breakthrough in providing cognitive tools to the specialist, the student and interested 
others. Heretofore, subject specialists were the primary group with the skills and 
understandings to produce concept structures. The ideabases and associated algorithms 
help expand the group with these capabilities. 
An important objective from idea analysis is to describe gaps, weaknesses, and/or 
inconsistencies in existing knowledge, thus leading to representation of potential new 
research strategies. 
This integration of organizational and comparative procedures simplifies the 
difficult and tedious process involved in formal analysis of: 
1. What is known; 
2. What is thought to be known; and 
3. What might be known. 
The components of the relationally structured ideaase are the essential ingredients 
from the literature. These are: 
1. Bibliographic data-authors, title, source; 
2. Ideas-these are defined as thoughts (Guralnik, 1979) in the form 
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of couplets of terms or phrases. Each couplet is a linkage 
provided by the authoL An example of a couplet is: 
TREATMENT is linked with SURVIVAL 
The linkage offers increased understanding of the content of the document 
compared with separately displayed key words or phrases. For example, the 
treatment-survival couplet clearly shows that the author considered (and probably studied) 
the relationship(s) between treatment and survival. 
The individual terms do not provide the same understandings. Individually, 
treatment or survival suggest that the author considered those terms but there is no 
indication as to how or for what purpose. With the couplet of terms as a single entity, 
it is easier to combine that thought with others to form a concept. A concept is defined 
as a set of thoughts which form a description of a component in a topic (Sharkey, 1986; 
Soergel, 1985). A concept can also be thought of as mental construct and unit of thought 
used to structure knowledge and to perceive the surrounding world. A system of 
concepts/terms provides a mental ordering of knowledge to visualize and clarify 
relationships between concepts and terms. 
Even retrieval is made more accurate and efficient. Articles dealing with the 
individual terms would be eliminated from consideration. Only those in which the 
authors linked the terms involved would be included. Boolean combinations cannot 
match that clarity of understanding (Cooper, 1988; B. H. Weinberg, 1988). 
Analysis of the scientific literature using techniques and concepts from idea 
analysis is based on the premise that specific information processing techniques may be 
applied in a formalized algorithmic fashion. Further, this analytic process will provide 
results which match those from specialists in the subject O. M. Weiner & Horowitz, 
1992; J. M. Weiner, Horowitz, & Latinwo, 1987). The process involved does not 
attempt to duplicate any procedure performed by subject specialists. Instead, the idea 
analysis process is focused on the management of ideas and the arrangement of those 
ideas using organizational models. 
The application of these techniques to the scientific literature dealing with brain 
tumors is illustrative. The purpose of the analysis is to identify the possible strategies 
which might be used in constructing new clinical trial protocols. The strategies formed 
will be compared with those used in actual protocols developed by clinical investigators. 
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Construction of the Ideabase 
A brief description of the process used to build the ideabases is given below. 
Four procedures are involved. 
1. Selection of Journals 
S. C. Bradford, in 1934, introduced a procedure for the selection of journals 
pertinent to a defined subject. He postulated that the majority of the information would 
be found in a small number of journals. Subsequent work elevated that hypothesis to a 
law (Brookes, 1969; Drott, 1981; Egghe, 1985). Sen and Kundra (1986) showed an 
example of this in their study of alcohol fuels. They used the bibliographic database to 
identify the journals most likely to contain articles dealing with the subject. Their 
analysis of alcoholic fuels adds evidence that Bradford's law correctly described the 
occurrence of information in terms of sets of journals. This close linkage between sets 
of journals and major amounts of information potential in a field raises questions 
regarding the worth of bibliographic databases constructed using index terms as the basis 
for retrieval of articles. 
Poynard and Conn (1985) and J. M. Weiner, Stowe, Fuller, et al (1982) 
compared the accuracy and completeness of articles retrieved using selected index terms 
versus selected journal sets. Both studies found that the number of articles retrieved, 
based on the information provided in the index terms database, constituted less than 60% 
of the articles dealing with the subject. Inconsistency and inaccuracy in indexing also 
were demonstrated. 
Construction of an idea database system begins with the selection of journals 
having a high probability of including articles related to the subject. A total of 63 
journals were included in the search for articles. Table 2 shows the number of articles 
contributed by each journaL The journals are broken down into four groups. Group 1 
contains 4 journals that contributed 50% of the articles. Group 2 contains 10 journals 
that contributed 30% of the articles. The 35 journals in Group 3 contributed 19% and 
the journals in Group 4 contributed the remaining 1 %. Bradford's law (Bradford, 1939) 
appeared to hold when considering the number of articles selected, as 14 (22 %) journals 
contributed 80% of the articles. 
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Table 2 
Number of Articles From Journals Containing Numerical Relationship Displays 
During the Period 1979-1992-Grouped According to Bradford's Law 
Group 1 
Journal of Neurosurgery 
International Journal of Radiation, Oncology 
Biology, Physics 
Cancer 
Acta N eurochirurgica 
Group 2 
Journal of Neuro-Oncology 
Child's Brain 
Journal of Clinical Oncology 
American Journal of Clinical Oncology 
Radiology 
Annals of Neurology 
Cancer Research 
Journal of Neurology, Neurosurgery, and Psychiatry 
N euroradiology 
Cancer Treatment Reports 
Group 3 
Proceeding American Society of Clinical Oncology 
British Journal of Cancer 
JNCI: Journal National Cancer Institute 
Neurology 
British Journal of Radiology 
European Journal of Cancer 
Radiotherapy Oncology 
Acta Neurologica Scandinavica 
International Journal of Cancer 
American Journal of Epidemiology 
Journal of Neuropathology and Experimental Neurology 
Medical and Pediatric Oncology 
Anticancer Research 
Archives of Neurology 
191 
149 
111 
107 
88 
45 
32 
27 
26 
26 
23 
23 
22 
20 
19 
16 
15 
15 
12 
12 
10 
9 
8 
8 
7 
7 
7 
7 
Table 2-Continued 
Group 3-Continued 
New England Journal of Medicine 
Proceedings Society International Oncologia Paediatric 
Tumori 
AJR: American Journal of Radiology 
Journal of Pediatrics 
Journal of Surgical Oncology 
American Journal of Diseases of Children 
JAMA 
Lancet 
Neoplasma 
Cancer Bulletin 
Archives of Diseases of Children 
Journal of the Neurosurgical Sciences 
Acta Paediatrica Scandinavica 
American Journal of Clinical Pathology 
American Journal of Pediatrics Hematology Oncology 
Cancer Chemotherapy Pharmacology 
Clinical Radiology 
Journal of Cancer Research 
Oncology 
Recent Results of Cancer Research 
Group 4 
American Journal of Public Health 
Cancer Treatment Reports 
European Neurology 
Pediatric Research 
American Journal of Obstetrics and Gynecology 
Brain 
Canadian Medical Association 
Cancer Letter 
Developmental Medicine and Child Neurology 
Frontier Radiation Therapy 
Journal of Neurology 
Journal of the Neurologic Sciences 
Proceedings American Association Cancer Research 
European Journal of Oncology 
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6 
6 
6 
5 
5 
5 
5 
5 
5 
5 
4 
4 
3 
3 
3 
3 
3 
3 
3 
3 
3 
2 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
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2. Extraction of Ideas in the Numerical Relationships 
The articles selected for inclusion in the idea database are those which display 
ideas in numerical relationships in tables and/or graphs. Figure 2 illustrates these 
formats. The contingency table is shown in Figure 2A. The characteristics linked by 
the author were age and sex. The numbers in the table represent the joint distribution 
of the attributes of these two characteristics. The technician is instructed to identify the 
characteristics in the numeric relationship and to computerize the fact that these 
characteristics (i.e., Age and Sex) were studied together. 
Figure 2B shows the scattergram format linking characteristics A and B. Each 
point shows the joint occurrence of a value of A and of B. The pattern of points 
represents the possibilities of demonstrating a positive, negative, or null relationship. 
Again, the technician is required to extract the fact that the author studied characteristics 
A and B and that this linkage was supported by data. 
Figure 2C shows the format used in displaying comparisons of time-associated 
event distributions. This format is used in engineering applications involving life-stress 
testing and in clinical trial research. The distributions representing the two treatments 
are being compared with respect to time. The measure used in the comparison shown 
in 2C is the percent surviving. The technician extracted the fact that the treatments were 
linked with the length of survival time. This relationship typically is labeled as treatment 
and survival time. 
Figure 2 
Examples of Numeric Relationship Displays 
Ao Contingency Table 
Young I AGE 
Old 
Bo Scattergram 
HISTOLOGY 
Co Time Event Distribution 
PERCENT 
SURVIVAL 
SEX 
Male Female 
20 10 
15 30 
STAGE 
TREATMENT A 
TREATMENTB 
TIME 
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3. Computerization of the Ideas and Associated Descriptors 
The idea database is a relational file, as shown in Figure 3. Citation, author, 
title, and relationships are linked using the document identification number. Secondary 
files, i.e., institution names, journal titles, and variate labels are linked with their 
primary files. Each of the secondary files is used to translate the numerical code used 
in the primary record to the actual name of the item for displays and reports. The 
translation of institution names, journal titles, and variate labels is performed by the 
microcomputer. The use of numeric codes simplifies the entry of data and processing 
of the material. There are four primary records. The first three are used to produce 
citations. The fourth record is used in the analysis of the ideas. By linking the 
institution code (from the author record) and year published (from the citation record) 
with the relationship record, analyses of ideas can be oriented by institution and/or by 
time. 
Figure 3 
Idea Database Structure 
I Document ID Number I 
I 
I I I I 
Author Citation Title Relationships 
Record Record Record Record 
I I I 
Institution Journal Variate 
Vocabulary Vocabulary Vocabulary 
4. Preparation of Bibliographic Records 
The computerization of the bibliographic information is accomplished by using 
programs which simplify data entry as much as possible. The author program asks for 
the name of the author and, if the author has been entered previously, automatically 
supplies the institution information. The title program is a straightforward data entry 
program. The citation program also allows for straightforward entry of the journal code, 
year, volume, and pages. The numeric codes for journal titles, institution names, and 
variate labels are supplied by separate programs. The structure of the relationship record 
is shown in Figure 4. This record is constructed using the concept of minimal data 
entry. The fields which must be entered each time are the two numbers representing the 
idea expressed in a numerical relationship display. 
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Figure 4 
Computerization of the Extracted Data 
Document ID Variate 1 Variate 2 P Value Page Defining Variates 
1 34 360 .05 10 411 163 
1 34 3 0 14 411 374 
2 3 7 .9 178 134 1861 
TRANSLATION OF COMPUTER RECORD 
1 Time Survival Treatment .05 10 A.L.L. Clin. Stage 
1 Time Survival Age 0 14 A.L.L. Race 
2 Age Sex .9 178 N.H.L. Histology 
The relationship record conveys the following information: In document ####, the 
variates # and # were linked by the author. The linkage was reported to be statistically 
significant/not significant. The graph/table was found on page ### of the journal. The 
relationship was studied in disease #. The factors #, #, #, #, and # were used to further 
clarify the nature of the relationship being studied. 
All of the entry programs allow for editing of the records before storage. 
Idea Processing 
Once the ideabase has been built, the ideas can be organized to provide concept 
structures. 
Primary Organizational Model 
The organizational model (Peto et aI, 1976, 1977; J. M. Weiner, 1979) used in 
arranging the ideas is one which is well recognized in clinical medicine. The model is 
used to display the interrelationships between factors which describe the patients studied, 
the characteristics of the disease involved, the therapeutic interventions applied, and the 
results of such manipulations. Graphically, the model is: 
OUTCOME FACTORS <--> TREATMENT FACTORS <--> DEFINING FACTORS 
where the defining factors are: 
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1. Those describing ENVIRONMENTAL conditions; 
2. Those describing PERSONAL factors relative to the patients; 
3. Those describing DISEASE factors important in describing the 
similarities and differences among the patients in terms of the 
disease and related conditions. 
The model states that: 
Patients defined specifically by the environmental, personal 
and disease factors, which together make up a complete 
description of the clinical group, will receive specific 
therapeutic interventions. These interventions are intended 
to effect changes in important measures of well-being. 
These outcome factors are: 
1. Measures of survival; 
2. Measures of disease control; 
3. Measures of adverse treatment effect; 
4. Measures of quality of life. 
Identification oj Ideas in Clinical Research Strategies 
The steps in identifying ideas of value in formulating clinical research strategies 
are designed to provide the information required by the organizational modeL The steps 
are: 
1. Identify all ideas linking important measures of outcome to factors 
in the other categories; 
2. Identify all ideas linking each of the other category factors, so that 
a more comprehensive concept structure representing the subject 
can be constructed; 
3. Simplify and generalize the terms involved, so that the concepts 
inherent in the subject can be clarified; 
4. Identify the gaps and omissions in the concept structure which 
would result in the development of new research strategies. 
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Measures of Outcome 
Important measures of therapeutic progress and patient well-being frequently are 
based on survival. There are several different ways of describing this phenomenon. 
These are: 
1. As a dichotomous variable-alive vs dead; 
2. As a continuous measure of time-length of survival from an 
arbitrary starting point; 
3. As a continuous measure of time with additional concern for other 
outcome qualities. These measures of survival time often are 
augmented by measures of disease control. The variables involved 
include: 
I. Disease free survival 
II. Event free survival 
III. Progression free survival 
IV. Recurrence free survival 
V. Relapse free survival 
Each variable describes a different nuance of disease control and survival and each 
involves a slightly different group of patients. 
Factors Related to Outcome 
The major categories of factors linked by investigators in clinical trial research 
to measures of outcome are those defining the patient group studied, the disease 
characteristics of interest, and the therapeutic interventions used. As each factor in one 
of these categories is identified, the terms related to it also are identified. In that way, 
the components making up the complete concept structure can be identified. The process 
is as follows: 
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Figure 5 
Steps in the Identification of Concept Structure 
Step 1. Identify links with the outcome factor. 
OUTCOME FACTOR 
I 
I I I I 
TREATMENT DISEASE PERSONAL ENVIRONMENTAL 
FACTORS FACTORS FACTORS FACTORS 
Step 2. Identify links with related factors and other outcome factors. 
OUTCOME FACTOR 
I 
I I I I 
TREATMENT DISEASE PERSONAL ENVIRONMENTAL 
FACTORS FACTORS FACTORS FACTORS 
I I I I 
RELATED RELATED RELATED RELATED 
FACTORS FACTORS FACTORS FACTORS 
I I I I 
OUTCOME OUTCOME OUTCOME OUTCOME 
FACTORS FACTORS FACTORS FACTORS 
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Ideas Involving Measures of Survival 
There are two principal themes associated with Exhibits 1 through 8. The first 
is to introduce different measures of survival and to show the ideas (Le., couplets of 
terms) describing each form of survival. To accomplish this, the phrase representing the 
form of survival is entered at the top of the exhibit. The terms/phrases linked to it are 
shown within the body of the exhibit. 
The second theme is to introduce a simplification and organizational process 
which is useful in bringing related ideas together and in forming descriptions of subjects. 
These descriptions should be similar to those prepared by subject experts. 
The simplification and organizational process involves the following steps: 
1. Arrange the ideas in the categories defined by the clinical trial 
model; 
2. Remove replicate ideas so that the individual ideas remaining can 
be assessed for their informational value; 
3. Remove synonymous ideas by recoding couplets or by introducing 
new summary ideas which replace existing couplets. 
Measures of Survival 
The first of the outcome factors to be considered is disease free survival. This 
measure of survival considers those patients who, as a result of the therapeutic 
intervention, experienced an apparent total elimination of the disease so that, clinically, 
the patients appear to be restored to normal function. 
A failure using this measure of survival would be based on: 
1. Death due to cancer; 
2. Death due to adverse effects of treatment once normal function had 
been accomplished; 
3. Recurrence of the cancer. 
Exhibit 1 gives the ideas linked with disease free survival. Each idea record has 
the following fields: 
1. The related term/phrase; 
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2. The document identification number. 
These fields are separated by commas. 
Replicate records, that is, those containing the same idea but from different 
articles and/or sentences, are shown in this display. This exhibit represents the most 
specific information available relative to each idea in the knowledge resource. 
Ideas with terms which are synonymous to one another also are present in this 
exhibit. An example of that is age and age at diagnosis. While the two can represent 
different situations, for the most part, the terms can be collapsed to form one summary 
term. In this example, age can replace other age-designated terms. 
The information contained in the exhibit is divided into the categories suggested 
by the organizational modeL As seen, there was one environmental factor-institution. 
There were two personal factors-age and sex. The disease factors involved described 
the disease in terms of measures of: 
1. Diagnosis; 
2. Extent or severity of disease; 
3. Patient performance; and 
4. Site of disease. 
Treatment factors included chemotherapy, radiation therapy, and surgery . 
Characteristics, such as protocol, time between treatments, time surgery to RT, and time 
of treatment, represent general descriptors of the treatment process. These characteristics 
are shown under the label-General Treatment Factors. There were two other outcome 
factors linked with disease free survival. One was infection as an adverse event of 
treatment. The other was the patient's compliance with the requirements of the treatment 
plan. In clinical trial research, this plan is called a protocoL 
The exhibit shows the classification of the ideas into subcategories. This 
classification is part of the simplification and generalization process required to develop 
the concept structure. As will be seen in future exhibits, the detailed information is not 
lost in this translation process. Instead, simplification adds external layers of 
information, so that the resulting knowledge structure offers the complete range of 
information, from broad strokes and generalizations to details regarding the replication 
and variety of ideas making up the subject. 
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Exhibit 1 
DISEASE FREE SURVIVAL and RELATED FACTORS in BRAIN TUMORS 
DISEASE FREE SURVIVAL 
and 
ENVIRONMENTAL FACTORS 
Institution,02571 
PERSONAL FACTORS 
Age,02627 
Age,03200 
Age,03317 
Age ,03405 
Age at Diagnosis,03129 
Sex,02627 
Sex,03129 
Sex,03317 
Sex,03584 
DISEASE FACTORS 
Diagnosis 
Acoustic Neuroma,03028 
Brain Stem Tumor,03200 
Brain Tumors,02480 
Brain Tumors,02483 
Ependymoma ,02627 
Ependymoma, 03584 
Glioblastoma Multiforme,03393 
High-Grade Astrocytoma, 03405 
Low-Grade Astrocytoma,03167 
Medulloblastoma,02831 
Medulloblastoma,02571 
Medulloblastoma,02576 
Medulloblastoma,02627 
Medulloblastoma,02909 
Medulloblastoma,03076 
Medulloblastoma,03151 
Medulloblastoma,03288 
Medulloblastoma,03304 
Medulloblastoma,03317 
Medulloblastoma, 03 391 
Medulloblastoma,03412 
Exhibit 1-Continued 
Diagnosis-Continued 
Meningeal Gliomatosis,02483 
Optic Glioma,03449 
Optic Glioma,03066 
PNET,03129 
Extent/Severity of Disease 
Brain Stem Involvement, 02627 
Clinical Stage,02831 
Clinical Stage,03317 
Duration of Symptoms,03200 
Extent of Disease,02571 
Labeling Index,03167 
Metastases Grade,03317 
Number of Prognostic Findings,03584 
Prognosis,03317 
Residual Disease,03317 
Risk Group,03076 
Risk Group,03304 
Risk Group,03412 
TNM Stage,03317 
Tumor Volume,03317 
Tumor Extent,02576 
Tumor Grade,03584 
Performance 
Performance Status, 03405 
Site of Disease 
Primary Tumor Site,03200 
Tumor Location,03584 
Tumor Site,03317 
TREATMENT FACTORS 
Chemotherapy 
Chemotherapy , 02627 
Chemotherapy,03129 
Chemotherapy, 035 84 
Maintenance Chemotherapy, 02627 
Multiagent Chemotherapy ,03288 
Multiagent Chemotherapy,03317 
General 
Protocol,03151 
Time Between Treatments,02627 
Time Surgery to RT,03317 
41 
Exhibit 1-Continued 
General-Continued 
Time of Treatment,02576 
Time of Treatment,03391 
RT Field,02480 
Radiation Dose,03449 
Radiation Dose,02627 
Radiation Dose,03066 
Radiation Dose,03393 
Radiation Dose,03584 
Surgery 
Degree of Resection,03317 
Extent of Surgery ,03584 
Shunt,03317 
Surgery,03028 
Surgical Procedure,02627 
Surgical Procedure,02909 
Surgical Procedure,03129 
Surgery/RT Combination 
Surgery & Postoperative RT,03028 
OUTCOME FACTORS 
Infection Toxicity, 03 317 
Protocol Compliance,02627 
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Exhibit 2 shows the same data as Exhibit 1, now simplified and generalized. 
Replicates and synonymous terms have been processed. In doing that, the location 
information, represented by document identification numbers, disappears, leaving the 
ideas in their conceptual form. This description represents two steps up in terms of 
generalization. The first step involved removal of replicate ideas after recoding 
synonymous terms. The second step involved removal of location data from the 
remaining ideas. 
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Exhibit 2 
SIMPLIFIED DESCRIPTION of DISEASE FREE SURVIVAL and RELATED 
FACTORS in BRAIN TUMORS 
DISEASE FREE SURVIVAL 
and 
ENVIRONMENTAL FACTORS 
Institution 
PERSONAL FACTORS 
Age 
Sex 
DISEASE FACTORS 
Diagnosis 
Acoustic Neuroma 
Astrocytoma 
Brain Stem Tumor 
Brain Tumors 
Ependymoma 
Glioblastoma Multiforme 
Medulloblastoma 
Meningeal Gliomatosis 
Optic Glioma 
PNET 
Extent/Severity of Disease 
Clinical Stage 
Prognosis 
Residual Disease 
Performance 
Performance Status 
Site of Disease 
Primary Tumor Site 
Tumor Location 
TREATMENT FACTORS 
Chemotherapy 
Chemotherapy 
Maintenance Chemotherapy 
General 
Protocol 
Time Between Treatments 
Time Surgery to RT 
Time of Treatment 
Exhibit 2-Continued 
Radiation Therapy 
RT Field 
Radiation Dose 
Surgery 
Degree of Resection 
Shunt 
Surgical Procedure 
Surgery/RT Combination 
Surgery & Postoperative RT 
OUTCOME FACTORS 
Infection Toxicity 
Protocol Compliance 
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Exhibit 3 gives the relationships found for the outcome factor-event free 
survival. This measure of survival includes the following conditions of failure: 
1. Patients with and without residual disease may be included in the 
group to be analyzed. 
2. All patients must show stability of their disease process. Those 
without residual disease are assumed to have been restored to 
normal function. Those with residual disease must show that their 
disease is stable, that is, known signs and symptoms must not 
change. 
3. Failure events include: 
• Death due to any cause; 
• Extension of disease; 
• New episodes of disease. 
As such, event free survival is a more extensive and conservative measure of the 
therapeutic benefit associated with an intervention strategy. The categories observed are 
essentially the same as with disease free survivaL" 
Exhibit 3 
EVENT FREE SURVIVAL and RELATED FACTORS in BRAIN TUMORS 
EVENT FREE SURVIVAL 
and 
ENVIRONMENTAL FACTORS 
Randomization Compliance,03213 
PERSONAL FACTORS 
Age,03213 
Age,03262 
Age,03434 
Race,03213 
Race, 03434 
Sex,03213 
Sex,03434 
DISEASE FACTORS 
Diagnosis 
Astrocytoma,03213 
Medulloblastoma,02581 
Medulloblastoma,02885 
Medulloblastoma,03262 
Medulloblastoma, 03434 
Medulloblastoma ,03506 
Extent/Severity of Disease 
Cell Differentiation,02581 
Cell Differentiation,02885 
Mitosis,03213 
Necrosis,03213 
Pathology,03213 
Tumor Stage,03434 
Site of Disease 
Primary Tumor Site,03213 
TREATMENT FACTORS 
Chemotherapy 
Multiagent 
Chemotherapy,03506 
Chemotherapy/RT Combination 
Chemotherapy & RT,03213 
Chemotherapy & RT,03262 
Chemotherapy & RT,03434 
Surgery 
Degree of Resection,03213 
Degree of Resection,03434 
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Simplification and Organization of Ideas 
The range and variety of terms with corresponding sets of ideas associated with 
survival represent one level of complexity in the use of scientific literature. A second 
level deals with the simplification and organization of the ideas representing a given 
subject. 
The process which prepares the ideas for building new descriptions of topics and 
for creating new research strategies is both simple and logical. The objectives are: 
1. To eliminate unnecessary redundancy by removing replicate ideas; 
2. To eliminate unnecessary complexity by recoding all synonymous 
terms/phrases; 
3. To construct optimal repositories by introducing labels which 
adequately summarize the various terms/phrases introduced by 
different authors. 
Exhibit 4 shows the first step in simplification of the display of the ideas linked 
with survival. In this step, replicate ideas are removed. This is illustrated by bolding 
the first occurrence of the replicate ideas. The remaining ideas contain independent 
terms as well as those which are synonymous, or nearly so, with others. Once again, 
the Iocational data have been removed. While this step eliminates a large number of 
individual ideas, the display shows the wealth of specific information which remains. 
Exhibit 4 
SIMPLIFIED PRESENTATION of IDEAS INVOLVING MEASURES of 
SURVIVAL: 
SURVIVAL 
and 
COLLAPSE of REPLICATE and SYNONYMOUS TERMS 
ENVIRONMENTAL FACTORS 
Geography 
Institution 
Residence 
Study Conduct 
Eligible Patients 
Study Group 
PERSONAL FACTORS 
Age 
Race 
Age at Diagnosis 
Age at First Treatment 
Age at Randomization 
Age at Relapse 
Age at Surgery 
Sex 
Occupation 
DISEASE FACTORS 
Diagnosis 
Diagnosis 
Corrected Diagnosis 
Astrocytoma 
Anaplastic Astrocytoma 
Anaplastic Foci Astrocytoma 
Gemistocytic Astrocytoma 
Giant Cell Astrocytoma 
High-Grade Astrocytoma 
Low-Grade Astrocytoma 
Brain Tumors 
Acoustic Neuroma 
Benign & Malignant Brain Tumors 
Brain Stem Tumor 
CNS Tumor 
Craniopharyngioma 
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Exhibit 4-Continued 
Brain Tumors-Continued 
Malignant Brain Tumor 
Spinal Cord Astrocytoma 
Glioma 
Anaplastic Glioma 
Brain Stem Glioma 
High-Grade Glioma 
Low-Grade Glioma 
Malignant Glioma 
Oligodendroglioma 
Optic Glioma 
Glioblastoma 
Glioblastoma Multiforme 
Craniopharyngioma 
Ependymoma 
Epilepsy 
Germinoma 
Intracranial Germ Cell Tumor 
Pineal Germinoma 
Medulloblastoma 
Meningeal Gliomatosis 
Meningioma 
Pineal Tumor 
Pineal Region Tumor 
PNET 
Supratentorial Tumor 
Diagnostic Method 
CT Contrast 
CT Contrast Enhancement Area 
CT Scan 
CT Scan At Diagnosis 
Diagnostic Accuracy 
Imaging Findings 
Skull X-Rays 
Extent/Severity of Disease 
Alpha-l Acid Glycoprotein 
Alpha-l Antitrypsin 
Ataxia 
BNDZ 
BUdR 
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Exhibit 4-Continued 
Extent/Severity of Disease-Continued 
BUdR Labeling Index 
Biopsy 
Blood Group 
C-erbB2 Oncogene 
Calcification 
Cell Nuclear Abnormality 
Cell Concentration 
Cell Density 
Cell Differentiation 
Cell Type 
DNA Content 
DNA Ploidy 
Ganglioside Pattern 
Gene Amplification 
Glial Fibrillary Acidic Protein 
Glomerular Arrangement 
Karyotype 
Ki-67 Labeling Index 
Labeling Index 
Nuclear Index 
Nuclear Polymorphism 
Nuclear Profile Area 
Nuclear Volume 
Nucleolar Organizer Region Proteins 
Nucleus Score 
Oligodendroglial Cells 
Pleomorphism 
Pons Cranial Nerves 
Rosette Cells 
S+G2M Cell Phase 
Sheep Erythrocyte Binding Lymphocytes 
S Phase 
Clinical Stage 
Altered Consciousness 
Aphasia 
Clinical Presentation 
Concomitant Disease 
Dementia 
Disease Status 
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Exhibit 4-Continued 
Clinical Stage-Continued 
Duration of Preoperative Symptoms 
Duration of Symptoms 
Edema 
Extent of Visual Loss 
Focal Deficit 
Hemiparesis 
Headaches 
Hematoma 
Hemorrhage 
Herination 
History of Seizures 
Hydrocephalus 
Initial Symptoms 
Language Deficit 
Level of Consciousness 
Motor Performance 
Neurologic Deficit 
Neurologic Function 
Neurological Score at Admission 
Number of Prognostic Findings 
Papilloedema 
Paresis 
Personality Changes 
Preoperative Visual Loss 
Previous Treatment 
Prior Chemotherapy 
Prior Glioma 
Prognosis 
Psychic Impairment 
Recurrent Anaplastic Astrocytoma 
Recurrent Astrocytoma 
Recurrent Glioblastoma 
Recurrent Glioma 
Recurrent Medulloblastoma 
Responders 
Risk GrouP" 
Seizure Pattern 
Seizures 
Sensory Loss 
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Exhibit 4-Continued 
Clinical Stage-Continued 
Signs - Long Tract 
Signs On Admission 
Symptoms at Presentation 
Visual Grade 
Corpus Callosum 
Cranial Nerve Abnormality 
Cranial Nerve Paresis 
Midbrain Cranial Nerves 
Cyst 
Microcyst 
Number of Cysts 
Tumor Cyst 
Desmin 
Desmoplasia 
Endothelial Hyperplasia 
Endothelial Proliferation 
Epidermal Growth Factor 
Epidermal Growth Factor Receptor 
FC Binding Lymphocytes 
Glucocorticoid Dependency 
Glucose Consumption 
HLA-Dr Antigen 
Haptoglobin 
Histology 
Histologic Diagnosis 
Histologic Feature 
Histology Grade 
Degree of Anaplasia 
Grading System 
Kernohan Grade 
Histology Verified 
Histopathologic Tumor Score 
Astrocytoma Grade 
Pathological Stage 
Revised Tumor Grade 
Histopathology 
Pathology 
Staging Method 
Human Lymphoblastoid IFN-A 
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Exhibit 4-Continued 
Extent/Severity of Disease-Continued 
Immunoglobulin 
Infection 
Laser Power 
Lymphatic Infiltration 
Lymphocyte Autologous Blocking 
Lymphocyte Homologous 
Blocking 
Lymphocyte Count 
Metabolic Rate 
Mitosis 
Mitotic Index 
Necrosis 
Monocyte Lysis 
Number of Lobes 
0-6 Alkylguanine DNA Alkyltransferase 
Oxygen P02 
P53 Protein 
Pyruvate Kinase 
Time Between Symptoms & Biopsy 
Time from Diagnosis to Progression 
Time of Diagnosis 
Tissue Plasminogen Activator Antigen 
Tuberous Sclerosis 
Tumor Extent 
Brain Stem Involvement 
Brainstem Enlargement 
Invasive Tumor 
Leptomeningeal Involvement 
Metastases 
Tumor Grade 
Tumor Appearance 
Tumor Color 
Tumor Compartments 
Tumor Decrease 
Tumor Demarcation 
Tumor Density 
Tumor Differentiation 
Tumor Focality 
Tumor Glucose Uptake 
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Exhibit 4-Continued 
Tumor Grade-Continued 
M Stage 
WBe 
Performance 
Malignancy Features 
Malignancy Grade 
Mesenchyma Score 
Perivascular Infiltrates 
Tumor Metabolism 
Tumor Origin 
Tumor Removed 
Tumor Size 
Tumor Stage 
Tumor Type 
Tumor Volume 
Tumor/Whole Brain Glucose Metabolism 
Vascular Hypertrophy 
Vascular Proliferation 
Vascularity 
Vessel Frequency 
Vessel Size 
Karnofsky Performance Score 
Performance Status 
Tumor Site 
Primary Tumor Site 
Tumor Laterality 
Tumor Location 
Tumor Side 
Tumor Site in Brain 
TREATMENT FACTORS 
Chemotherapy 
Chemotherapy 
CCNU 
CCNU/PCB/VCR 
Chemotherapy Dose 
LEV 
Multiagent Chemotherapy 
Number Courses of 
Chemotherapy 
Type of Chemotherapy 
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Exhibit 4-Continued 
Chemotherapy/RT Combination 
Chemotherapy & RT 
Chemotherapy/RT /Surgery Combination 
Chemotherapy & RT & Surgery 
Multimodal Treatment 
Chemotherapy/Surgery Combination 
Chemotherapy & Surgery 
Immunotherapy 
Immunotherapy 
Immune Reactivity 
Immunotherapy/RT Combination 
Immunotherapy & RT 
Non-Specific 
Protocol 
Number of Protocols 
Treatment 
Route 
Salvage Therapy 
Time Between Treatments 
Time First Symptom to Surgery 
Time of Treatment 
Treatment Delay 
Treatment Schedule 
Radiation Therapy 
Actual Dose 
Dose Pions/Photons 
Radiation Dose 
Adequate Technique 
Time/Dose/Fraction 
Brachytherapy 
Fast Neutron RT 
MNI & Neutron RT 
Neutron RT 
RT & Radiation Enhancer 
RT & Fluosol 
RT Boost Dose 
RT Field 
RT Neuroret 
RT Volume 
Radiation Field Size 
54 
Exhibit 4-Continued 
Radiation Therapy-Continued 
Radiosensitizers 
Superfractionated RT 
Type of Interstitial Implant 
Type of Laser 
Type of RT 
Type of RT Boost 
Type of Radiation 
Steroids 
Steroid Dependency 
Steroid Dose 
Steroids 
Surgery 
Extent of Surgery 
Lobectomy 
Second Surgery 
Surgery 
Surgical Procedure 
Surgical Resection 
Surgery/RT Combination 
RT & Surgery 
Surgery & Postoperative RT 
Transplantation Therapy 
Autologous BMT 
OUTCOME FACTORS 
Toxicities 
Nausea & Vomiting 
Toxicity 
Relapse/Response 
Number of Relapses 
Recurrence 
Relapse Site 
Response 
Response Second Treatment 
Time to First Relapse 
Time to Tumor Progression 
Treatment Failure 
Protocol Conduct 
Protocol Compliance 
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The second step eliminates the synonymous terms and reduces the total size of 
the display. Exhibit 5 shows this second step of simplification. The involved terms have 
been recoded and collapsed into one new set. To illustrate that process, the new term 
is bolded. 
Exhibit 5 
ELIMINATION of REPLICATE TERMS and SYNONYMOUS TERMS: 
SURVIVAL and RELATED FACTORS in BRAIN TUMORS 
SURVIVAL 
and 
ENVIRONMENTAL FACTORS 
Geography 
Institution 
Residence 
Study Conduct 
PERSONAL FACTORS 
Age 
Race 
Sex 
Occupation 
DISEASE FACTORS 
Diagnosis 
Diagnosis 
Brain Tumors 
Acoustic Neuroma 
Astrocytoma 
Glioma 
Glioblastoma 
Glioblastoma Multiforme 
Craniopharyngioma 
Ependymoma 
Epilepsy 
Germinoma 
Medulloblastoma 
Meningeal Gliomatosis 
Pineal Tumor 
PNET 
Supratentorial Tumor 
Exhibit 5-Continued 
Diagnostic Method 
CT Contrast 
Skull X-Rays 
Extent/Severity of Disease 
Alpha-l Acid Glycoprotein 
Alpha-l Antitrypsin 
Ataxia 
BNDZ 
BUdR 
BUdR Labeling Index 
Biopsy 
Blood Group 
C-erbB2 Oncogene 
Calcification 
Cell Nuclear Abnormality 
Clinical Stage 
Corpus Callosum 
Cranial Nerve Abnormality 
Cyst 
Desmin 
Desmoplasia 
Endothelial Hyperplasia 
Epidermal Growth Factor 
FC Binding Lymphocytes 
Glucocorticoid Dependency 
Glucose Consumption 
HLA-Dr Antigen 
Haptoglobin 
Histology 
Human Lymphoblastoid IFN-A 
Immunoglobulin 
Infection 
Laser Power 
Lymphatic Infiltration 
Lymphocyte Autologous Blocking 
Lymphocyte Count 
Metabolic Rate 
Necrosis 
Number of Lobes 
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Exhibit 5-Continued 
Extent/Severity of Disease-Continued 
0-6 Alkylguanine DNA Alkyltransferase 
Oxygen P02 
P53 Protein 
Pyruvate Kinase 
Time Between Symptoms & Biopsy 
Tissue Plasminogen Activator Antigen 
Tuberous Sclerosis 
Tumor Extent 
Tumor Grade 
WBC 
Performance 
Karnofsky Performance Score 
Tumor Site 
Primary Tumor Site 
TREATMENT FACTORS 
Chemotherapy 
Chemotherapy & RT 
Chemotherapy & RT & Surgery 
Chemotherapy & Surgery 
Immunotherapy 
Immunotherapy & RT 
General 
Protocol 
Treatment 
Radiation Therapy 
Actual Dose 
Adequate Technique 
Brachytherapy 
Fast Neutron RT 
RT 
RT & Radiation Enhancer 
RT Boost Dose 
RT Field 
RT Neuroret 
RT Volume 
Radiation Field Size 
Radiosensitizers 
Superfractionated RT 
Type of Interstitial Implant 
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Exhibit 5-Continued 
Radiation Therapy-Continued 
Type of Laser 
Type of RT 
Type of RT Boost 
Type of Radiation 
Steroids 
Steroid Dependency 
Steroid Dose 
Surgery 
Extent of Surgery 
Lobectomy 
Second Surgery 
RT & Surgery 
Surgery 
Transplantation Therapy 
Autologous BMT 
OUTCOME FACTORS 
Toxicities 
Relapse/Response 
Number of Relapses 
Recurrence 
Relapse Site 
Response 
Response Second Treatment 
Time to First Relapse 
Time to Tumor Progression 
Treatment Failure 
Protocol Conduct 
Protocol Compliance 
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Exhibit 6 shows the ideas after the simplification procedure. This display 
identifies the principal nodes linked with survivaL The emphasis on treatment 
approaches from 1979 through 1992 is evident. In addition, disease factors can be 
divided into four important sub-categories. This exhibit is important in illustrating the 
end-result of the concept building operation and the beginning point for concept 
demonstration. 
Exhibit 6 
PRINCIPAL NODES CONTRIBUTING to the CONCEPT STRUCTURE: 
SURVIVAL and RELATED FACTORS in BRAIN TUMORS 
SURVIVAL 
and 
ENVIRONMENTAL FACTORS 
PERSONAL FACTORS 
DISEASE FACTORS 
Diagnostic Method 
Extent/Severity of Disease 
Performance 
Tumor Site 
TREATMENT FACTORS 
Chemotherapy 
Chemotherapy/RT 
Chemotherapy/RT /Surgery 
Chemotherapy/Surgery 
Immunotherapy 
Immunotherapy/RT 
Radiation Therapy 
Steroids 
Surgery 
Surgery/RT 
Transplantation Therapy 
OUTCOME FACTORS 
Toxicities 
Relapse/Response 
Building "Concept Structure" Descriptions 
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The process illustrated in Exhibits 4 through 6 is intended to assist in the building 
of succinct descriptions of subjects. The premise underlying the procedure is that ideas 
can be combined to form such descriptions. Further, a series of established algorithms 
used in data and text processing can be of value in performing this task. An important 
issue illustrated by these exhibits is the need to reduce the complexity and specificity in 
building the general descriptions. The simplification and organization procedures shown 
perform this desired function without eliminating the detailed data necessary for in-depth 
review and analysis of specific points. Instead, the summarization adds extemallayers 
of increasing generalization, so that the final structure resembles the desired format of 
a knowledge base with its total capability to provide wide-ranging forms of information. 
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Exhibit 7, for example, illustrates the expansion of detailed information as the 
concept structure is unfolded in a descriptive way. Exhibit 6 gives the tight overview. 
Exhibit 7 presents that information plus one important subnode. This process could be 
continued until the results in Exhibit 4 are revealed. 
Exhibit 7 
EXPANSION of EXTENT/SEVERITY of DISEASE NODE: 
SURVIVAL and RELATED FACTORS in BRAIN TUMORS 
SURVIVAL 
and 
ENVIRONMENTAL FACTORS 
PERSONAL FACTORS 
DISEASE FACTORS 
Diagnostic Method 
Extent/Severity of Disease 
Cell Nuclear Abnormality 
Clinical Stage 
Cranial Nerve Abnormality 
DNA Content 
Histology 
Histology Grade 
Tumor Extent 
Performance 
Tumor Site 
TREATMENT FACTORS 
Chemotherapy 
Chemotherapy/RT 
Chemotherapy/RT /Surgery 
Chemotherapy/Surgery 
Immunotherapy 
Immunotherapy/RT 
Radiation Therapy 
Steroids 
Surgery 
Surgery/RT 
Transplantation Therapy 
OUTCOME FACTORS 
Toxicities 
Relapse/Response 
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Validity of Combining Ideas to Form Structures 
While an obvious and infonnative correspondence should exist between the 
infonnation provided in Exhibits 1 through 7, the validity of the process involved in 
producing such summaries had not been established until recently. Publications from 
artificial intelligence emphasized the argument that decision processes could be developed 
which were similar to those which might be used by subject specialists. While that is 
correct, it is not compelling. A number of authors have shown that idea analysis could 
be used to match descriptions from experts. These reports, representing a variety of 
subjects, could be considered as convincing anecdotes, motivating interest and attention 
in the process. 
A recent analysis set the stage for demonstrating that ideas could be combined 
as was predicted in theoretical discussions of entropy in infonnation (Gleick, 1987; 
Tabah, 1992). The steps in developing a test of the interrelationships among the 
variables in ideas are: 
1. Identify variables which are linked with survival; 
infonnation is given in Exhibit 4. 
(That 
2. Identify the variables which represent those more frequently 
appearing; 
3. Detennine the amount of cross-linking among the high frequency 
variables. 
Cross-linking describes the degree of interrelationship among the variables. 
This is frequently expressed by the logic statement: 
If A is related to B and A is related to C. then Band C should be related. 
Analysis of cross-linking can detennine the validity of that postulate applied to the 
important nodal tenns making up the topic. 
To illustrate this approach, 29 variables shown in Exhibit 8 were selected for 
further expansion. These represented the frequently occurring ideas from Exhibit 4. For 
each of these high frequency tenns, the couplets containing those tenns were retrieved. 
The percentage of high frequency tenns cross-linked with each index tenn was 
calculated. 
Of these 29 variables, 24 were linked with age as well as with survivaL The 
linkages with age are shown in Exhibits 9 and 10. Exhibit 9 displays the variables linked 
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with age. Exhibit 10 displays the variables liked with age and survival after 
simplification. Fourteen summary variables are shown. Four personal factors were 
involved in developing a display of cross-linking. Similarly, three disease 
factors-laboratory studies, diagnostic factors, and staging factors-were related to both 
variables. Treatment included transplant, chemotherapy, surgery and radiation therapy. 
Outcome factors involved disease control measures, toxicities, and quality of life 
determinations. 
Exhibit 8 
VARIABLES SELECTED for EXPANSION of RELATIONSHIPS 
PERSONAL FACTORS 
Age 
Sex 
DISEASE FACTORS 
Anaplastic Astrocytoma 
Astrocytoma 
Ependymoma 
Glioblastoma 
Glioma 
Histology 
Medulloblastoma 
Mitosis 
Necrosis 
Oligodendroglioma 
Performance Status 
Tumor Grade 
Tumor Site 
Tumor Size 
Tumor Stage 
Tumor Type 
TREATMENT FACTORS 
Chemotherapy 
Chemotherapy & RT 
Chemo & RT & Surgery 
RT 
RT Field 
Radiation Dose 
Degree of Resection 
Extent of Surgery 
Surgery 
Surgical Procedure 
RT & Surgery 
Exhibit 9 
RELATIONSHIPS WITH AGE AFTER SIMPLIFICATION and 
ORGANIZATION 
ENVIRONMENTAL FACTORS 
Cancer in Relatives 
Family History of Cancer 
Farm Residence 
Incidence 
Institution 
Marriage 
Profession 
Protocol 
Study Group 
PERSONAL FACTORS 
Academic Ability 
Height 
IQ 
Intellectual Function 
Race 
Sex 
DISEASE FACTORS 
Alpha-l Antitrypsin 
Benign & Malignant Brain Tumors 
Astrocytoma 
Anaplastic Astrocytoma 
Gemistocytic Astrocytoma 
High-Grade Astrocytoma 
Low-Grade Astrocytoma 
Pilocytic Astrocytoma 
Spinal Cord Astrocytoma 
Brain Stem Tumor 
Craniopharyngioma 
Ependymoma 
Subependymoma 
Germinoma 
Glioma 
Pineal Germinoma 
Glioblastoma Multiforme 
Glioblastoma 
High-Grade Glioma 
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Exhibit 9-Continued 
Glioma-Continued 
Low-Grade Glioma 
Malignant Glioma 
Prior Glioma 
Intracranial Germ Cell Tumor 
Malignant Spinal Tumor 
Medulloblastoma 
Meningeal Gliomatosis 
Meningioma 
Oligodendroglioma 
Optic Glioma 
PNET 
Pineal Region Tumor 
Pineal Tumor 
Teratoma 
Diagnostic Method Sequence 
Aphasia 
BUdR Labeling Index 
Biopsy Method 
Biopsy 
Cell Type 
CNS Involvement 
Cortical Atrophy 
CT Features 
CT Contrast 
Calcification 
Clinical Presentation 
Clinical Stage 
DNA Content 
DNA Ploidy 
Disease Status 
Endocrine Function 
Fine Motor Skills 
Follicle Stimulating Hormone 
Functional Status 
Ganglioside Pattern 
Gene Amplification 
Glasgow Outcome Score 
Glial Fibrillary Acidic Protein 
Growth Hormone 
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Exhibit 9-Continued 
DISEASE FACTORS-Continued 
Growth Rate 
HVA 
Headaches 
Histology 
Histologic Diagnosis 
Histologic Feature 
Histology Grade 
Initial Symptoms 
Labeling Index 
Language Ability 
Leg Length 
Leukoencephalopathy 
Lymphatic Infiltration 
Lymphocyte Migration 
M Stage 
MNI 
MRI Post-Treatment 
Malignancy Grade 
Memory 
Menopausal Status 
Mental Retardation 
Mental Status 
Metastases 
Metastatic Site 
Mitosis 
Morphology 
Myopathy 
Necrosis 
Neurologic Progression 
Neurologic Symptoms 
Neurological Score at Admission 
Neurological Sequelae 
Nuclear Cell Size 
Number of Cell Types 
Papilloedema 
Pathology 
Performance Status 
Pineal Calcification 
Plasma Carcinoembryonic Antigen Level 
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Exhibit 9-Continued 
DISEASE FACTORS-Continued 
Pneumatic Compression 
Preoperative Visual Loss 
Previous Treatment 
Primary Tumor Site 
Prognosis 
Pulmonary Embolism - Deep Vein Thrombosis 
Risk Group 
Risk of Cancer in Child 
Risk of Death 
Risk of Menopause 
Risk of Neoplasm 
Seizures 
Sella Turcia 
Signs & Symptoms 
Signs On Admission 
Signs Present at Diagnosis 
Sitting Height 
Sitting Height/Leg Length 
Smoking Status 
Smoking 
Symptom Severity 
Symptoms Present at Diagnosis 
Symptoms at Presentation 
Symptoms 
Testicular Volume 
Thromboembolism 
Tumor Appearance 
Tumor Compartments 
Tumor Extent 
Tumor Grade 
Tumor Location 
Tumor Origin 
Tumor Progression Score 
Tumor Site 
Tumor Size 
Tumor Type 
Vascular Hypertrophy 
Vascular Proliferation 
Ventricular Dilatation 
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Exhibit 9-Continued 
DISEASE FACTORS-Continued 
Visual-Motor Skills 
Wechsler Full Scale 
Wechsler Performance Scale 
Wechsler Verbal Scale 
Well Being 
TREATMENT FACTORS 
Autologous BMT 
BCNU 
BNDZ 
Brachytherapy 
CBDCA 
Chemotherapy & RT & Surgery 
Chemotherapy & RT 
Chemotherapy 
Extent of Surgery 
Hyperfractionated RT 
Immunotherapy & RT 
Interstitial RT 
MNI & Neutron RT 
Multiagent Chemotherapy 
Neutron RT 
RT & Surgery 
RT Field 
RT 
Radiation Dose 
Radiosensitizers 
Superfractionated RT 
Surgery & Postoperative RT 
Surgical Approach 
Surgical Procedure 
Surgical Resection 
Type ofRT 
OUTCOME FACTORS 
Chemosensitivity 
Death Rate 
Disease Free Interval 
Disease Free Survival Time 
Event Free Survival Time 
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Exhibit 9-Continued 
OUTCOME FACTORS-Continued 
Length of Life 
Long-Term Results 
Mortality Rates 
Postoperative Visual Loss 
Progression Free Survival Time 
Pulmonary Toxicity 
Quality of Life 
Recurrence 
Recurrence Time 
Recurrent Disease 
Recurrent Astrocytoma 
Recurrent Glioma 
Relapsed High Grade Glioma 
Recurrent Medulloblastoma 
Reinduction Time 
Relapse Free Survival Time 
Relapse Time 
Relapse 
Response 
Survival Following Surgery 
Survival Time 
Survival 
Time Local Control 
Time Progression to Death 
Time Recurrence Free 
Time to Failure 
Time to Tumor Progression 
Toxicity 
Treatment Failure 
Treatment Result 
Tumor Decrease 
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Exhibit 10 
RELATIONSHIPS WITH SURVIVAL and AGE 
SURVIVAL 
AGE 
PERSONAL FACTORS 
Height 
IQ 
Race 
Sex 
DISEASE FACTORS 
Laboratory Studies 
Diagnosis 
Staging 
TREATMENT FACTORS 
Transplant 
Chemotherapy 
Surgery 
Radiation Therapy 
OUTCOME FACTORS 
Disease Control 
Toxicity 
Quality of Life 
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Exhibit 11 shows the relationships linking chemotherapy and survival after 
simplification and organization. There were 26 high frequency variables linked with 
survival which could be linked with chemotherapy. Of these, 21, or 81 % were so 
linked. 
Exhibit 11 
RELATIONSHIPS WITH CHEMOTHERAPY AFTER SIMPLIFICATION and 
ORGANIZATION 
SURVIVAL 
CHEMOTHERAPY 
PERSONAL FACTORS 
DISEASE FACTORS 
TREATMENT FACTORS 
Steroids 
Surgery 
Type of RT 
OUTCOME FACTORS 
Disease Control 
Toxicity 
Growth Rate 
Hearing Loss 
Hematologic Toxicity 
Infection Toxicity 
Liver Toxicity 
Nausea & Vomiting Toxicity 
Neurologic Toxicity 
Pulmonary Toxicity 
Renal Toxicity 
Skin Mucous Membranes Toxicity 
Toxicity Alopecia 
Toxicity Grade 
Toxicity Type 
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Exhibit 12 shows the relationships with histology after simplification and 
organization. Forty-six percent of the high frequency variables linked with survival also 
were linked with histology. 
Exhibit 12 
RELATIONSHIPS WITH HISTOLOGY AFTER ORGANIZATION 
SURVIVAL 
HISTOLOGY 
ENVIRONMENTAL FACTORS 
PERSONAL FACTORS 
DISEASE FACTORS 
TREATMENT FACTORS 
Multiagent Chemotherapy 
Radiation Therapy 
Surgery & Postoperative RT 
OUTCOME FACTORS 
Disease Control 
Recurrence 
Relapse 
Reinduction Time 
Response 
Toxicity 
Quality of Life 
Exhibit 13 summarizes the analysis of relationships among the high frequency 
terms linked with survival. The cross-linkages are given as percentages of the number 
of terms connected to each of the high frequency terms. 
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Exhibit 13 
PERCENT LINKAGES AMONG HIGH FREQUENCY VARIABLES LINKED 
WITH SURVIVAL 
PERSONAL FACTORS 
Age 
Sex 
DISEASE FACTORS 
Anaplastic Astrocytoma 
Astrocytoma 
Ependymoma 
Glioblastoma 
Glioma 
Histology 
Medulloblastoma 
Mitosis 
Necrosis 
Oligodendroglioma 
Performance Status 
Tumor Grade 
Tumor Site 
Tumor Size 
Tumor Stage 
Tumor Type 
TREATMENT FACTORS 
Chemotherapy 
Chemotherapy & RT 
Chemo & RT & Surgery 
RT 
RT Field 
Radiation Dose 
Degree of Resection 
Extent of Surgery 
Surgery 
Surgical Procedure 
RT & Surgery 
PERCENTAGE LINKED 
86% 
71% 
54% 
77% 
73% 
86% 
86% 
46% 
77% 
39% 
44% 
77% 
68% 
50% 
75% 
46% 
14% 
86% 
81% 
61% 
56% 
43% 
46% 
79% 
46% 
46% 
50% 
75% 
50% 
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Table 3 summarizes the statistical distribution of cross-link findings. Five 
variables-one from personal factors, three from disease factors and one from treatment 
factors-make up the group, with 80% to 90% of such linkages. None of the variables 
had linkages exceeding 90%, and only one, tumor stage, had a low linkage. 
Table 3 
Distribution of Percent Linkages for Frequently Occurring Variables in Ideas 
Involving Survival 
Percent Distribution Variables with 
Linkages Linkages 
f % cum % cum f 
90-100 -- -- 100 
80-90 5 17 100 29 age, glioma, 
glioblastoma, 
tumor type, chemo 
70-80 8 28 82 24 sex, astro, ependy, 
medullo, oligo, 
rad dose, tumor site, surg 
proc 
60-70 2 7 54 16 perform status, 
chemo & RT 
50-60 5 17 47 . 14 anap astro, 
tumor grade, chemo, RT, 
surg, 
chemo & RT & surg, 
RT & surg 
40-50 7 24 30 9 histology, necrosis, 
tumor size, RT, 
RT field, deg resect, 
extent surg 
30-40 1 3 6 2 mitosis 
20-30 
-- -- 3 -- --
10-20 1 3 3 1 tumor stage 
Total 29 100 
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Using the test for outliers, tumor stage was found to be significantly different from the 
rest of the distribution. The recalculated distribution, with tumor stage removed, is 
shown in Table 4. 
Table 4 
Recalculated Distribution of Percent Linkages for Frequently Occurring Variables 
in Ideas Involving Survival. Tumor Stage Removed From the Distribution 
Percent Distribution Variables with 
Linkages Linkages 
f % cum % cum f 
90-100 -- -- 100 
80-90 5 18 100 28 age, glioma, 
glioblastoma, 
tumor type, chemo 
70-80 8 29 83 23 sex, astro, ependy, 
medullo, oligo, 
rad dose, tumor site, surg 
proc 
60-70 2 7 54 15 perform status, 
chemo & RT 
50-60 5 18 47 13 anap astro, 
tumor grade, chemo, RT, 
surg, 
chemo & RT & surg, 
RT & surg 
40-50 7 25 29 8 histology, necrosis, 
tumor size, RT, 
RT field, deg resect, 
extent surg 
30-40 1 4 4 1 mitosis 
Total 28 100 
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With a sample size of 29, this test of neighbor membership compares the ratio of 
differences between the third smallest observation with the smallest and the twenty-sixth 
(third largest) with the smallest. The test statistic comparing this ratio of adjusted ranges 
is: 
r(32) = [X(3) - X(1)]/[X(26) - X(1)] 
= 43 - 14 I 86 - 14 
= .403 (P < 0.05) 
Table 5 shows the expected cumulative distribution of the linkage percentages if 
the observations were from the uniform random distribution. A 95 % confidence interval 
for this population distribution was calculated using the Kolmogorov-Smirnoff procedure 
(Dixon & Massey, 1983). The table also gives the observed cumulative distribution 
before and after removal of the outlier, tumor stage. As seen, the observed distributions 
are partly outside of the 95 % confidence bounds, suggesting that the observed 
distributions are not random. 
Table 5 
Cumulative Distribution and 95% Confidence Interval for the Hypothesis that the 
Percent Linkages Were Sinlple Random Observations 
Percent Percent 
Percent Percent Percent Percent Observed Observed 
Linkages Cumulative Lower Upper with without 
Distribution Bound Bound Tumor Tumor 
Stage Stage 
10 -- 34 0 0 
10-20 20 -- 44 3 0 
20-30 30 6 54 3* 0* 
30-40 40 16 64 6* 4* 
40-50 50 26 74 30 29 
50-60 60 36 84 47 47 
60-70 70 46 94 54 54 
70-80 80 56 100 82 83 
80-90 90 66 -- -- --
* Observed distributions outside the 95 % CI for random distribution. 
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These data agree with the premise that, if A is linked with B and A is linked with C, one 
should expect B to be linked with C. In this example, let A be survival, B be age, and 
C some other frequently occurring variable linked with survival. 
An Algorithm for Building Concept Structures 
Given the confirmation that the ideas do form sensible clusters resembling 
concepts, there is a need to focus on those terms which form important nodes in a 
concept structure. As suggested by the exhibits and tables, the idea analysis approach 
focuses on the identification of nodal terms defined in terms of their high frequency of 
occurrence with the primary nodal term (survival, in this example) and with their high 
frequency of cross-linking. From Exhibit 13, the sequence of nodes considered would 
be: 
Summary 
1. Outcome Factors-Survival is the predominant variable of 
concern and was used to initiate the subsequent analyses. 
2. Personal Factors-Age had the largest percentage of links with 
the other high frequency variables; 86% of the high frequency 
terms had links with this variable. 
3. Disease Factors-There are several of these variables with high 
linkage percentage values. The more generalized variable found 
was tumor type (86%). Glioblastoma (86%) and glioma (86%) 
are examples of this general variable. The other variables 
associated with this node are astrocytoma (77 %), medulloblastoma 
(77%), oligodendroglioma (77%), and ependymoma (73%). 
These diagnoses are sufficiently important that many clinical trial 
protocols restrict patient entry to those with a specific diagnosis. 
Tumor site (75 %) and performance status (68 %) represent nodes 
which describe other components of the disease picture. 
4. Treatment Factors-There are three treatment approaches with 
high frequency linkages. These are: chemotherapy (81 %), 
radiation dose (79%), and surgical procedure (75%). The fact 
that brain tumors are treated using a multimodality approach is 
seen both by the high frequencies for the separate modalities and 
by the combinations also included as high frequency variables. 
An important question addressed by the idea analysis methodology was, "How 
do we identify the important ideas which may form the central core of a concept 
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structure describing the topic?" The focus on ideas identifies the important terms, as 
well as the ways in which these terms are connected one to another. The methodology 
also deals with the building of concept structures using the central set of ideas. 
The algorithms involved in this information processing procedure are simple in 
logic and performance. They incorporate techniques which are well established in data 
and/or text processing. The uniqueness of the approach is not in the analytic exercises, 
but in the data analyzed. Idea analysis is unique in focusing on ideas extracted from the 
scientific literature. 
The ideas are identified using a straightforward process from the graphs and 
tables given in the scientific documents. These numerical representations of relationships 
provide succinct, factual statements. In each case, the extracted idea represents a couplet 
of terms/phrases. These have been linked by the author and data supplied to show the 
nature and significance of the relationship. 
The idea analysis method simplifies the information to a statement of the form: 
Author ABC studied a relationship linking XXX with YYY. 
The couplet XXX < = = > YYY becomes the essential datum processed in building 
concept structures. 
A number of investigators have suggested that these couplets could be organized 
to build representations of topics in the form of concept structures which would resemble 
those prepared by subject specialists (Fuller et aL, 1982; Malogolowkin et aL, 1989; 
Wood, 1992). Employing a recently reported algorithm, the validity of using these 
couplets in forming concept structures was tested using the ideas from the brain tumor 
literature. The findings showed that the linkages were not simple random observations. 
Instead, the ideas were closely interrelated and the construction of concept structures was 
possible. 
Analysis of the interrelated, high frequency nodes suggested a research strategy 
of the following nature: 
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Figure 6 
Research Strategy 
DEFINING 
OUTCOME TREATMENT FACTORS 
I I I 
TREATMENT AGE, 
with TUMOR TYPE, 
SURVIVAL <---- CHEMOTHERAPY, <====> TUMOR SITE, 
RADIOTHERAPY, PERFORMANCE 
SURGERY STATUS 
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Chapter IV 
Results 
This chapter illustrates the idea analysis methodology as applied to ideas extracted 
the graphical and tabular displays in the brain tumor scientific literature. These 
sets are displayed as individual concept structures in Appendix A. A major 
tVallta~[e from the idea analysis approach lies in the ability to depict a particular course 
action or research strategy adopted by investigators when they build a new research 
. Three research protocols were used to illustrate the development process. 
protocols were developed, respectively, by the Radiation Therapy Oncology Group 
, M.D. Anderson Cancer Center (MDA), and the Brain Tumor Study Group 
Fifty brain tumor treatment protocols from the Physician's Data Query (PDQ) 
were retrieved. Ideas were extracted describing the patient groups, disease 
, treatments employed, and outcome measures studied. These idea sets are 
individually as concept structures (in Appendix A) and summarized in a 
:onc:ent structure depicting the frequency of terms used in treatment protocols (Figure 
Finally, this display of treatment protocols was compared with a concept structure 
.v .... ".u ... the frequency of ideas in the brain tumor literature. 
, ..... ""uu·<u Analysis of Literature 
The contrast between idea analysis and usual or manual approaches will be 
first by showing the typical materials available to the investigator. In the 
iI~iIJ[laniUal approach, the investigator must identify key terms/phrases and the references 
contain those terms. The investigator must then retrieve the articles, screen those 
relevance, select the ones of interest, read the articles for content, extract pertinent 
, organize those data, and prepare a summary description. The process is lengthy 
.involves a considerable amount of clerical activity. The following primary steps are 
1. Retrieval and copying of articles; 
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2. Extraction of data; 
3. Organization-sorting, copying, appending, merging. 
The intellectual components are involved essentially in preparation of the summary 
description. 
The idea analysis approach is based on the formation of rules for processing the 
literature so that the clerical features can be separated from the intellectual. If 
successful, literature analysis can be managed in a formalized fashion. The resulting 
process would be comparable to that employed in laboratories engaged in chemical or 
physical analyses. 
A typical first step in the manual approach is to identify key terms involved in the 
subject. One such category of terms includes the chemotherapeutic agents previously 
studied in brain tumor treatment. Exhibit 14 displays such a list of terms, together with 
document numbers referring to the articles containing those terms. This display is taken 
from an in-depth analysis of the articles involved. As such, the display accurately 
displays the chemotherapeutic agents used to treat patients with brain tumors. Any 
casual or non-specific references to chemotherapy agents have been avoided, so that the 
referral suggested in Exhibit 14 is guaranteed to direct the investigator to an article 
containing the term as it was used in a treatment regimen. 
Exhibit 14 
CHEMOTHERAPY REGIMENS STUDIED 
(Regimen, Doc #s) 
Source: Encyclopedia of Ideas-Brain Tumors 
(1979-early 1992) 
ACNU 2855,3611 
ACNU-IA 3240 
ARJ\-C2608, 2875, 2877, 2888, 3010, 3093, 3462, 3552 
ARJ\-C, CCNU, CDDP, CPM, HU, PCB, PRED, VCR 2875 
ARJ\-C, CCNU, CDDP, CPM, HU, PCB, PREDL, VCR 2875,3010,2608,3093 
ARJ\-C, CCNU, CDDP, DTIC, HU, MEPREDL, PCB, VCR 3552 
ARJ\-C, CCNU, CDDP, DTIC, HU, PCB, PRED, VCR 2875 
ARJ\;..C, CCNU, CDDP, DTIC, HU, PCB, PREDL, VCR 2875,3010,3093 
ARJ\-C, CDDP, VP-16 3084, 3462 
AT-1253450 
AZQ 2585, 2589, 2590, 2816, 2915, 3078, 3126, 3199, 3234, 3629 
AZQ, BCNU 2915, 3234, 3629 
AZQ, PCB 2915 
AZQ-IA 2864 
Exhibit 14-Continued 
BCNU 2499, 2501, 2509, 2550, 2552, 2634, 2644, 2651, 2689, 2692, 
2734, 2789, 2813, 2841, 2843, 2896, 2897, 2915, 2944, 3000, 
3119, 3217, 3223, 3234, 3256, 3422, 3495, 3515, 3529, 3546, 
3553, 3563, 3572, 3585, 3629, 3633 
BCNU, 5-FU, RU, 6-MP 2908 
BCNU, CCNU, PCB, VCR 3495 
BCNU, CDDP 2894,3529,3585 
BCNU, DAG 2463,2599 
BCNU, DEX, PCB, VCR 3515 
BCNU, MP-6 3572 
BCNU, PCB, VCR 3422 
BCNU, TZT 2599 
BCNU-IA 2868, 3416 
BCNU-IA, CDDP-IA 2606, 3416 
BLEO 2499 
BNDZ, CCNU 3192 
BU 3260, 3544 
BUDR 3053, 3258, 3453, 3554, 3583, 3606 
CBDCA 2917,3400, 3518, 3607 
CBDCA, PRED 3607 
CCNU 2475, 2483, 2513, 2608, 2631, 2636, 2674, 2713, 2776, 2797, 
2875, 2877, 2888, 2918, 3010, 3093, 3172, 3192, 3213, 3256, 
3258, 3262, 3304, 3317, 3338, 3451, 3453, 3471, 3478, 3489, 
3495, 3506, 3521, 3528, 3552, 3559, 3579, 3632 
CCNU, 5-FU, RU, 6-MP 3085 
CCNU, CDDP, VCR 3304,3478 
CCNU, DEX 2631 
CCNU, DEX, PCB, VCR 3632 
CCNU, RU, PCB, VCR 3471 
CCNU, LND 3559 
CCNU, MTX-IT, VCR 3451 
CCNU, PCB, VCR 3506,3552,2648,3453,3489 
CCNU, PRED 3579 
CCNU, PRED, VCR 3317 
CCNU, VCR 3304, 3338 
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Exhibit 14-Continued 
CCNU, VM-262631 
CDDP 2577, 2607, 2608, 2615, 2875, 2877, 2884, 2888, 3010, 3060, 
3093, 3261, 3298, 3304, 3398, 3418, 3446, 3462, 3478, 3485, 
3512, 3513, 3516, 3529, 3552, 3585 
CDDP BASED REGIMENS 3470 
CDDP, CPM, DOX 2599 
CDDP, DAG, DOX, VCR 2599 
CDDP, VCR 3516, 3446 
CDDP, VP-16 3261, 3485 
CDDP-IA 2894,3177,3407,3416 
CDDP-IA, VP-16-IA 3407 
CPM 2608,2797,2875,2877,2943,3010,3093,3557 
CPM-HD 2652 
DAG, TZT, VP-16 2599 
DAG, VP-16 2599 
DAVA, SPG 3176 
DBD 3528, 2814 
DEX 2631,3017,3515,3632 
DFMO 3628 
DFMO, MGBG 3628 
DTIC 2608, 2875, 2877, 2888, 3010, 3093, 3552 
FCNU 3455 
GH 2967, 3263, 3300 
HC 2645 
HECNU 3170, 3293, 3492 
HU 2513, 2608, 2689, 2713, 2841, 2875, 2877, 2888, 3010, 3076, 
3093, 3217, 3256, 3412, 3471, 3552 
HU, PCB 3412 
LDM 3221 
LND 3559 
MECCNU 2651, 2813 
MEHDZ 2797 
MEPREDL 3552 
MGBG 3628 
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MNI 2509, 2555, 2566, 2587, 2603, 2622, 2636, 2639, 2656, 2825, 
2841, 2876, 2896, 2953, 2978, 3223, 3403 
MOAB 425 3517 
MP-63572 
MTX 2797 
MTX-IT 2645, 2776, 2943, 3451 
NM 3351, 3434, 3582 
NM, PCB, PRED, VCR 2489,3155,3434,3582 
NM, PCB, VCR 3351 
PCB 2501, 2608, 2841, 2875, 2877, 2888, 2915, 3010, 3076, 3093, 
3217, 3256, 3258, 3351, 3412, 3422, 3434, 3453, 3471, 3489, 
3495, 3506, 3515, 3528, 3552, 3582, 3632 
PCB, PRED, VCR 2489 
PCNU 2497,2582,3035,3048 
PRED 2475, 2483, 2608, 2875, 2877, 2888, 2918, 3010, 3093, 3213, 
3262, 3317, 3434, 3579, 3582, 3607 
PREDL-HD 2501, 2841 
SPG 2925 
STEROIDS 3454 
SZC 2841, 3223 
TCNU 3617 
TG-63528 
TMX 3574 
TSPA 3260, 3544 
VBL 2797 
VCR 2475, 2483, 2608, 2645, 2713, 2776, 2875, 2877, 2888, 2918, 
3010, 3093, 3213, 3256, 3258, 3262, 3298, 3304, 3317, 3338, 
3351, 3422, 3434, 3446, 3451, 3453, 3471, 3478, 3489, 3495, 
3506, 3515, 3516, 3552, 3582, 3632 
VM-26 2674, 2841, 2877, 3217 
VP-16 3261, 3462, 3485, 3557 
VP-16-IA 3407 
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Appendix B shows the bibliographic entries for this set of articles. Armed with 
the information in Exhibit 14 and Appendix B, the investigator can then move into a 
major component of the clerical phase of literature analysis-retrieving, copying, and 
screening the articles. 
While the data in Exhibit 14 and Appendix B are valuable and essential in 
identifying the correct articles, the investigator has no a priori knowledge of how the 
term/phrase is used in the article. The investigator has no awareness of the relationships 
between the chemotherapeutic agent and other measures of management of the disease. 
These relationships must be discovered by reading the articles, extracting the ideas and 
facts involved, and organizing those in some appropriate fashion. This lengthy and 
elaborate process must be performed each time the underlying topic is considered. 
Idea Analysis of Literature 
Idea analysis seeks to correct this enormous exercise in redundancy by 
identifying, extracting and storing the ideas inherent in an article. The analysis shown 
here illustrates the identification of important ideas by their use by the authors in tabular 
or graphic displays. The focus on the Results sections of scientific articles is not without 
merit. The principal reason for preparing a scientific article is to present to the scientific 
world new findings relevant to a particular problem. The other sections of the 
article-Introduction, Methods, Discussion, Conclusions-are valuable in providing 
mechanisms whereby the authors can position their findings with those from other 
investigators. 
The ideas from the tables and graphs have been shown to be complete and 
sufficient to prepare concept structures describing major problems. Yamaguchi, 
Horowitz, Latinwo, Weiner (1987) showed this finding by comparing a detailed 
extraction of all ideas from the text of articles dealing with lymphomas with the ideas 
extracted from only the tables and graphs from those same articles. The concept 
structures were essentially the same. The differences in time and effort between the two 
identification-extraction approaches was statistically different. As expected, the 
graph/table approach took less time and was easier to accomplish. 
Exhibit 15 shows the chemotherapy-survival related ideas from the brain tumor 
literature. The linkages between the principal term/phrase at the top of the display-
survival-and the terms/phrases related to that principal term/phrase are given in this 
exhibit. The outline format shows the major terms/phrases, i.e., primary nodes and the 
terms linked to them. In this way, the outline depicts a concept structure. 
Exhibit 15 
IDEAS INVOLVING CHEMOTHERAPY 
Survival 
CHEMOTHERAPY REGIMENS 
Personal Factors 
Age 
Marriage 
Sex 
Smoking Status 
Disease Factors 
Benign & Malignant Brain Tumors 
Anaplastic Glioma 
Astrocytoma 
High-Grade Astrocytoma 
Brain Stem Tumor 
Glioblastoma 
Glioblastoma Multiforme 
Glioma 
High-Grade Glioma 
Recurrent Glioma 
Medulloblastoma 
Staging 
Astrocytoma Grade 
Histologic Diagnosis 
Pathological Stage 
Tumor Appearance 
Tumor Grade 
Tumor Location 
Tumor Site in Brain 
Tumor Size 
Tumor Type 
Clinical 
Presentation 
Duration of Preoperative Symptoms 
Epilepsy 
Handedness 
Initial Symptoms 
Level of Consciousness 
Necrotic Tumor 
Neurologic Symptoms 
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Exhibit 15-Continued 
Clinical-Continued 
Neurological Score at Admission 
Performance Status 
Pneumatic Compression 
Vision 
Treatment Factors 
Surgical Procedure 
Degree of Resection 
Steroids 
Glucocorticoid 
Type ofRT 
Brachytherapy 
Radiation Dose 
RT Field 
Outcome Factors 
Disease Control 
Disease Free Time 
Recurrence Site 
Response 
Time to Tumor Progression 
Toxicity 
Alopecia 
Growth Rate 
Growth Retardation 
Hearing Loss 
Hematologic Toxicity 
Leukopenia 
Nausea & Vomiting Toxicity 
Renal Toxicity 
Skin Mucous Membranes Toxicity 
Thrombocytopenia 
Quality of Life 
Survival Quality 
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This portion of the total concept structure shows the nodes and variables 
connected to the chemotherapy node. In tum, these relationships are linked via the 
specific chemotherapy to a measure of survival. The patient groups found deal with the 
majority of the diagnoses. As expected, chemotherapy has been employed in regimens 
for all of the specific brain tumor groups. As such, the label BENIGN AND 
MALIGNANT BRAIN TUMORS is appropriate to summarize the specifics of diagnosis. 
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The staging variables show the important elements studied-type, location, size. The 
clinical variables indicate the functional complications present at diagnosis. The 
treatment variables emphasize the importance of the surgery, steroids for management 
of swelling, and RT. That is, the combined modality approach has been tried and should 
be continued. Outcome variables show the lack of durable disease control and the 
adverse effects of the therapies tested. As such, there could be protocols which 
emphasize single modalities for newly diagnosed disease, employing either RT or surgery 
as well as multi-modality studies. 
A major advantage from the idea analysis approach lies in the ability to depict a 
particular course of action or research strategy adopted by investigators when they build 
a new research protocol. This is illustrated by the data shown in Exhibit 16 which gives 
the ideas from Exhibit 15 used in building protocol RTOG-9305. 
Exhibit 16 
IDEAS FROM EXHIBIT 15 USED IN RTOG-9305 
Personal Factors 
Age 
Disease Factors 
Glioblastoma Multiforme 
Staging 
Histologic Diagnosis 
Tumor Site in Brain 
Tumor Size 
Tumor Type 
Clinical 
Presentation 
Neurologic Symptoms 
Neurological Score at Admission 
Performance Status 
Treatment Factors 
Surgical Procedure 
Type ofRT 
Chemotherapy 
Outcome Factors 
Survival 
Toxicity 
Leukopenia 
Exhibit 16-Continued 
Toxicity-Continued 
Nausea & Vomiting Toxicity 
Renal Toxicity 
Thrombocytopenia 
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The Radiation Therapy Oncology Group (RTOG) introduced a protocol to study 
a new treatment approach in patients with brain tumors. The details of the protocol are 
provided by the National Cancer Institute in an online resource called PDQ. This 
resource enables investigators to determine the important studies being conducted. The 
details of the RTOG-9305 protocol obtained from the PDQ database are in Appendix C. 
Exhibit 16 shows the ideas used in the development of RTOG-9305. The primary 
nodal term is survival, representing the outcome factor to be improved by the new 
stereotactic radiotherapy regimen. 
The new element added in this protocol was the stereotactic radiosurgery, a 
form of carefully controlled, narrow beam radiation using various energy forms. Exhibit 
.. 17 gives the regimens employing radiotherapy and depicts the same type of information 
for this therapeutic approach as was shown for chemotherapy in Exhibit 14. 
Exhibit 17 
RT REGIMENS STUDIED 
(Regimen, Doc #s) 
Source: Encyclopedia of Ideas-Brain Tumors (1979-early 1992) 
RT 2453, 2461, 2469, 2471, 2473, 2475, 2476, 2480, 2482, 2483, 
2484,2487, 2491, 2494, 2499, 2501, 2504, 2509, 2511, 2513, 
2517, 2524, 2530, 2537, 2538, 2540, 2541, 2550, 2551, 2555, 
2569, 2570, 2571, 2574, 2575, 2576, 2578, 2581, 2591, 2592, 
2594, 2596, 2599, 2603, 2611, 2612, 2613, 2617, 2622, 2627, 
2630, 2635, 2637, 2639, 2640, 2642, 2644, 2645, 2647, 2649, 
2650, 2651, 2656, 2660, 2661, 2662, 2664, 2666, 2671, 2674, 
2676, 2677, 2679, 2682, 2689, 2692, 2698, 2703, 2710, 2712, 
2713, 2749, 2757, 2758, 2763, 2768, 2772, 2776, 2782, 2799, 
2801, 2805, 2806, 2813, 2825, 2829, 2831, 2834, 2841, 2855, 
2868, 2871, 2876, 2877, 2883, 2888, 2896, 2899, 2902, 2903, 
2905, 2907, 2909, 2912, 2914, 2916, 2918, 2923, 2926, 2932, 
Exhibit 17-Continued 
2933, 2934, 2935, 2938, 2939, 2942, 2943, 2945, 2950, 2959, 
2967, 2971, 2978, 2989, 2990, 3007, 3013, 3015, 3016, 3020, 
3022, 3024, 3028, 3029, 3039, 3040, 3042, 3053, 3061, 3064, 
3065, 3066, 3076, 3086, 3088, 3092, 3094, 3097, 3100, 3108, 
3109, 3113, 3119, 3120, 3121, 3125, 3127, 3129, 3133, 3139, 
3142,3143,3148,3153,3162,3172,3174,3175,3185,3187, 
3189, 3193, 3194, 3196, 3198, 3200, 3203, 3207, 3209, 3210, 
3213, 3217, 3223, 3225, 3226, 3235, 3236, 3242, 3244, 3249, 
3252, 3253, 3256, 3258, 3262, 3263, 3266, 3267, 3268, 3270, 
3271, 3273, 3274, 3275, 3279, 3283, 3284, 3288, 3289, 3295, 
3297, 3298, 3300, 3304, 3317, 3326, 3338, 3395, 3397, 3398, 
3399, 3402, 3405, 3406, 3408, 3409, 3412, 3415, 3418, 3422, 
3434, 3439, 3446, 3449, 3451, 3453, 3459, 3471, 3474, 3478, 
3485, 3495, 3506, 3512, 3513, 3516, 3521, 3526, 3546, 3547, 
3553, 3559, 3563, 3585, 3611, 3629, 3633 
RT-ACCELERATED FRACTION 3401 
RT-BRACHYTHERAPY 3026, 3141, 3164, 3246, 3468, 3471 
RT -ENDOCURIETHERAPY, INTRAOPERATIVE 3230 
RT-FRACTION 2636,2841 
RT-HEAVY CHARGED PARTICLE 2851 
RT-HIGH ACTIVITY 12513246 
RT-HYPERFRACTION 2492, 2513, 2566, 2622, 3114, 3205, 3223, 3421 
RT-INTERSTITIAL 3229, 3440 
RT-NEUTRON 2540, 2587, 2640, 2953, 3110, 3220, 3403, 3430 
RT-NEUTRON AND MNI 2587,2953 
RT-NEUTRON AND PHOTON 2977 
RT-PHOTON 2540, 2953, 2977, 3110 
RT-PHOTON AND MNI2953 
T-PHOTORADIATION 3049 
RT-PION 3252 
RT-SUPERFRACTION 2504, 3162 
90 
Comparing Exhibits 15, 16, and 17 shows the focusing which takes place as the 
SUbject specialist selects the elements of interest. While the conceptual structure, as 
Viewed by considering chemotherapy (Exhibit 15), identified type of RT as an important 
COmponent of treatment, the emphasis on surgery, chemotherapy or radiotherapy could 
be expected to depend on the interests and training of the subject specialists. Being a 
-oriented clinical trial organization, the RTOG focused their attention on 
newer radiotherapeutic approaches. The choice of BCNU as the chemotherapeutic agent 
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represented a desire for a standard "control." Exhibit 14 shows numerous studies 
employing that agent. Similarly, combining BCNU with conventional RT, another 
standard "control," provides a comparison regimen for the new combination regimen 
employing radiosurgery, conventional surgery, and BCNU. If radiosurgery is effective 
in reducing inoperable tumors, the combination employing that regimen should show 
increased survival because of better disease control. The randomized Phase III study 
design chosen is best suited to provide that information. 
The period covered by the Encyclopedia of Ideas (J. M. Weiner & Horowitz, 
1991a) did not include the more frequent use of radiosurgery as a treatment approach. 
As seen in Exhibit 17, during the time period covered by the Encyclopedia, only neutron 
RT and brachytherapy had been introduced. Exhibit 18 corrects this timing defect by 
providing recent abstracts (entered into MEDLINE after the Encyclopedia of Ideas was 
printed) involving radiosurgery. These were retrieved from Medline using a combination 
retrieval strategy employing the MeSH structure and natural language. 
Exhibit 18 
RECENT ABSTRACTS DEALING WITH 
RADIOSURGERY 
Source: MEDLINE (1992) 
TI: Brachytherapy of brain gliomas 
AU: Turowski-K; Trojanowski-T; Czochra-M 
SO: Neurol-Neurochir-Pol. 1992; Suppl 1: 130-6 
AB: Radiotherapy is considered presently the most advantageous supplementary method 
after surgical treatment for gliomas. The limitations of classical teletherapy cause that 
interstitial radiation may become preferable. The authors present the theoretical 
principles and practical application of brachytherapy in 10 cases of glioma. Closed 
radioactive sources were used in form of Il25 implanted stereotactically into brain 
tumours for a period sufficient for providing therapeutic radiation dose to the border of 
the tumour. The doses received by tumour borders ranged from 812 to 4560 cGy, and 
the mean dose was 2064 cGy. Five patients were given additionally 6000 cGy by 
teleradiotherapy. 
TI: Stereotactic radiosurgery using a linear accelerator. 
AU: Kyuma-Y; Hayashi-A; Kitamura-T; Yamashita-K; Muranishi-H; Hioki-M 
SO: Neurol-Med-Chir-Tokyo. 1992 Jul; 32(8): 572-7 
AB: A basic and clinical study of radiosurgery using the linear accelerator (Linac) system 
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for unremovable deep-seated brain tumors is reported. A Komai stereotactic ring was 
used to locate the target coordinates. The patient was laid on the Linac treatment table 
and held in the head fixation system. Irradiation was given in five positions. The dose 
profile by film dosimetry and Rando phantom was satisfactory. Seventeen tumors in 14 
patients were treated. Clinical or histological diagnoses were nine metastases, one 
benign and two malignant gliomas, one meningioma, and one craniopharyngioma. 
Tumor sizes were between 8 and 30 mm. Doses were between 12 and 30 Gy. Computed 
tomographic evaluation after 3 months of 12 tumors in 11 survivors showed one complete 
remission, three partial remission, six no change, and two partial deterioration. For 
progressive tumors, Linac radiosurgery results are excellent. 
TI: Surgery, radiation therapy, and chemotherapy for metastatic tumors to the brain. 
AU: Buckner-J 
SO: Curr-Opin-Oncol. 1992 Jun; 4(3): 518-24 
AB: Recent literature has confirmed patient age, Karnofsky status, and the extent of 
extracerebral tumor as independent prognostic variables in patients with cerebral 
metastases. In a good-risk population, surgery followed by radiation therapy is superior 
to radiation alone for treatment of patients with solitary metastases. Stereotactic 
radiosurgery is feasible in the same select patient population, but questions regarding the 
extent of delayed toxicity, tumor response, and the impact on quality of life and longevity 
remain to be answered. Studies of external beam radiation therapy for patients with 
_ brain metastases have shown that 1) misonidazole does not improve the response rate, 
quality of life, or duration of survival, 2) 5 Gy for six fractions and 3 Gy for 10 fractions 
produce similar results, and 3) reirradiation at doses of 25 Gy for tumors progressing 
after initial radiation may be feasible in a selected population of patients. Chemotherapy 
can affect regression of brain metastases in patients with small cell lung and breast 
carcinoma, as well as melanoma, but the overall contribution to the quality and duration 
of the patient's life compared with radiation alone is unknown. Intracarotid 
chemotherapy is feasible for patients with brain metastases, but substantial toxicity 
precludes its use outside of an investigational setting. Brain metastases remain an 
important cause of morbidity and mortality for patients with cancer, but the majority of 
patients still succumb to widespread systemic disease. The goal of treatment of brain 
metastases should be palliation with minimal infringement upon the patient's quality of 
life. 
TI: Stereotactic radiosurgery for acoustic tumors. 
AU: Linskey-ME; Lunsford-LD; Flickinger-JC; Kondziolka-D 
SO: Neurosurg-Clin-N-Am. 1992 Jan; 3(1): 191-205 
AB: Stereotactic radiosurgery is an important alternative treatment for carefully selected 
patients with acoustic tumors. We perform radiosurgery under local anesthesia, and 91 % 
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Exhibit IS-Continued 
of our patients have been discharged from the hospital within 24 hours after treatment. 
All returned to their preoperative level of function or employment within 5 to 7 days 
after treatment. Our current tumor control rate is 97%, but reduction in tumor size, 
judged by strict, objective criteria, was achieved in only 23 %. Our actuarial rate of 
useful hearing preservation after radiosurgery is 38 % at 1 year. Three tumors increased 
in size after treatment. Only one of the three demonstrated increased mass effect on 
surrounding brain structures by neuroimaging criteria. No increase has led to worsened 
clinical symptoms or has required surgical excision at this point in follow-up. The I-year 
rates for developing new facial or trigeminal neuropathies after radiosurgery were 30 % 
and 33 %, respectively. Cranial neuropathies had a delayed onset, with the median onset 
occurring after 5 to 6 months. The vast majority were partial at onset, and most 
improved over time. Communicating hydrocephalus requiring ventriculoperitoneal shunts 
developed after radiosurgery in four patients. Eight patients developed increased signal 
within adjacent brain parenchyma on T2-weighted MR imaging, consistent with edema 
or blood-brain barrier breakdown. It is unlikely that stereotactic radiosurgery using the 
gamma knife will obviate the need for microsurgical removal performed by skilled and 
experienced microsurgeons. However, radiosurgery is a safe and effective treatment for 
patients whose medical problems make surgery unacceptably dangerous, those with 
bilateral tumors or a tumor in their only hearing ear, those who have recurrent tumor 
despite surgical resection, or patients who refuse microsurgical excision. 
TI: Radiosurgery using a modified linear accelerator. 
AU: Alexander-E 3d; Loeffler-JS 
SO: Neurosurg-Clin-N-Am. 1992 Jan; 3(1): 167-90 
AB: Stereotactic radiosurgery using modified LINACs is a powerful new technique that 
offers a versatile method for administering high-dose radiation in a single session. 
Treatment-planning techniques currently in use enable individual isocenter field shaping, 
three-dimensional optimization of isocenter placement (including the use of multiple 
isocenters), and real-time analysis of isodose distribution in three dimensions relative to 
specifically defined anatomic structures from MR imaging or CT data. Modified linear 
accelerators offer successful control of both arteriovenous malformations and benign 
tumors (acoustic neuromas, craniopharyngiomas, and meningiomas), with results equal 
to the best series reported by users of the gamma knife or heavy-particle systems. More 
recent work indicates that radiosurgery may play an important role in controlling 
recurrent pediatric malignant tumors, metastatic cerebral lesions, and even malignant 
astrocytomas in some patients. Improved correlation of isodose distributions with 
imaging data allows for sophisticated analysis of results and specific complications, 
ultimately enabling improved patient care using this exciting new technique. 
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Exhibit IS-Continued 
TI: Stereotactic convergent-beam irradiation: its current prospects based on clinical 
results 
AU: Engenhart-R; Wowra-B; Kimmig-B; Hover-KH; Kunze-S; Wannenmacher-M 
SO: Strahlenther-Onkol. 1992 May; 168(5): 245-59 
AB: "Radiosurgery" is the term for a special concept in radiotherapy. It describes a 
percutaneous, stereotactically guided irradiation delivering a single high dose with 
collimated narrow beams. The precise stereotactic localization of the target point and 
a steep dose gradient outside the target volume allow the administration of high doses to 
a lesion without damage to adjacent normal tissue. Risk of necrosis, due to a dose 
volume relationship represents the limits of radiosurgery. Units for radiosurgery were 
designed at Stockholm using multiple external cobalt-60-gamma sources, at Boston 
operating with protons of a cyclotron, at Berkeley operating with helium ions accelerated 
by a synchrocyclotron. An attractive alternative to these complicated and expensive 
facilities is the use of a modified linear accelerator. At the German Cancer Research 
Center in Heidelberg such a system was developed and has been available for the 
treatment of patients since 1984. Though, data of over 100,000 patients with vascular 
malformations and cancer disease are available worldwide, the indication for this therapy 
is validated only for a minority of entities. In cases of inoperable arteriovenous 
malformations favourable results in achieving obliteration range between 60% and 100% 
were obtained. Median survival for solitary brain metastases with controlled, 
,extracerebral tumor diseases were between nine and twelve months. Up to now, 
advantages of stereotactic irradiation for benign tumor masses could not be proven. 
Therefore, randomized trials should be initiated in this field, considering decisive 
improvements in local tumor control with techniques of microsurgery and fractionated, 
postoperative radiotherapy during the last few years. 
TI: Patterns of recurrence of malignant astrocytoma following stereotactic interstitial 
brachytherapy with iodine-125 implants. 
AU: Agbi-CB; Bernstein-M; Laperriere-N; Leung-P; Lumley-M 
SO: Int-J-Radiat-Oncol-Biol-Phys. 1992; 23(2): 321-6 
AB: The pattern of tumor recurrence was studied in a series of 68 patients who were 
treated with interstitial brachytherapy for malignant astrocytoma. Thirty-six patients had 
newly diagnosed tumors and were treated following surgery and external beam therapy, 
While 32 were treated for recurrent tumors. Recurrence pattern was determined using 
computed tomography at the time of clinical deterioration. Thirty-eight percent of tumor 
recurrence occurred within the original tumor margin and 50 % occurred at the original 
site but extended beyond the initial margin. In all, 88.0% recurred at the initial tumor 
site, 71.4 % being confined to within 2 em of the pretreatment tumor borders while 6.0 % 
recurred intracranially outside of the initial tumor margin. One patient recurred with 
spinal metastasis while two patients developed systemic metastases. The significance of 
these findings is discussed. 
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Exhibit IS-Continued 
TI: Dynamic stereotactic radiosurgery in the palliative treatment of cerebral metastatic 
tumors. 
AU: Caron-JL; Souhami-L; Podgorsak-EB 
SO: J-Neurooncol. 1992 Feb; 12(2): 173-9 
AB: From October 1988 to April 1990, 9 patients with metastatic brain disease (11 
lesions) underwent stereotactic radiosurgery. All patients but two had recurrent 
metastatic disease after previous brain irradiation. The patients were treated with a 
single dose of 20 Gy, delivered to spherical target volumes ranging in diameters from 
10 mm to 30 mm and prescribed to the 90 % isodose surface. All tumors treated showed 
a favorable response to the treatment, with 4 patients achieving a complete radiological 
disappearance of the tumor. The majority of the patients experienced a rapid clinical 
improvement of their symptoms. No complications attributable to the radio surgical 
treatment were seen. Stereotactic radiosurgery appears to be an effective and safe 
treatment for patients with recurrent metastatic brain disease. 
TI: Stereotactic radiosurgical treatment of brain metastases. 
AU: Adler-JR; Cox-RS; Kaplan-I; Martin-DP 
SO: J-Neurosurg. 1992 Mar; 76(3): 444-9 
AB: In a series of 33 patients with reasonably controlled primary cancers, stereotactic 
radiosurgery was used to treat 52 brain metastases. After a mean radiological follow-up 
time of 5.5 months, six lesions (12%) had stabilized in size, 26 (50%) were significantly 
reduced, and 15 (29 %) had disappeared. One large melanoma metastasis progressed 
relentlessly despite treatment. Five lesions (9 %) had decreased in size slightly before 
enlarging. In two of these lesions, biopsy revealed only necrosis. In almost all cases, 
treatment was associated with decreased peritumoral edema. However, a group of 
patients with large metastases and extensive prior brain irradiation has been identified in 
whom prolonged symptomatic cerebral edema poses a problem. It is concluded that 
radiosurgery is a viable alternative to surgical resection for some cases of brain 
metastasis. 
Exhibit 19 shows the concept structure associated with radiotherapy as a single 
modality. As with chemotherapy, radiotherapy has been used in treating a large number 
of diagnostic subgroups. In patients receiving this form of treatment, conventional 
surgery will typically be employed first in order to establish the diagnosis and to debulk 
the tumor as much as possible. Given that situation, treatment factors studied emphasize 
the components making up radiotherapy. The studies contributing to this structure use 
conventional approaches. 
Survival 
RT 
Exhibit 19 
IDEAS INVOLVING RADIATION THERAPY 
Personal Factors 
Age 
Employment 
Height 
Income 
Marriage 
Race 
Sex 
Disease Factors 
Diagnosis 
Benign & Malignant Brain Tumors 
Astrocytoma 
Low-Grade Astrocytoma 
Craniopharyngioma 
Ependymoma 
Germinoma 
Glioblastoma Multiforme 
Glioma 
Medulloblastoma 
Meningioma 
Oligodendroglioma 
Optic Glioma 
Clinical 
Aphasia 
CT Contrast 
CT Scan At Diagnosis 
Duration of Symptoms 
Emotional Problems 
Motor Function 
Paralysis 
Performance Status 
Signs Present at Diagnosis 
Symptom Severity 
Symptoms at Presentation 
Tl Relaxation Time 
T2 Relaxation Time 
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Exhibit 19-Continued 
Clinical-Continued 
Visual Acuity 
Visual Field 
Visual Function 
Cell Characteristics 
Ganglioside Pattern 
Staging 
Histology 
Tumor Extent 
Tumor Location 
Tumor Site 
Tumor Type 
Treatment Factors 
Brachytherapy 
Radiation Dose 
Surgical Procedure 
Shunt 
Outcome Factors 
Disease Control 
Local Control 
Recurrence Site 
Recurrence Time 
Reinduction Time 
Response 
Time to Tumor Progression 
Toxicity 
Educational Quotient 
Hemiparesis 
IQ 
Quality of Life 
Health Condition Led to Job Change 
Health Perception 
Psychological-Emotional Sequelae 
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Exhibit 20 shows newer techniques in radiation therapy. The patient subgroups 
studied are those with poor prognosis. This is consistent with the selection of 
glioblastoma multiforme in RTOG-9305. If beneficial, the regimen employing 
radiosurgery could have a bigger impact and, hence, be more easily seen in patient 
groups showing relatively shorter disease control periods and shorter survival. Surgery 
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is the only other modality of treatment shown in the concept structure and that, in tum, 
is restricted to biopsy. 
Exhibit 20 
IDEAS INVOLVING NEW TECHNIQUES IN RADIATION THERAPY 
Survival 
NEW TECHNIQUES 
Arcs RT 
Hyperfractionated RT 
MNI & Neutron RT 
Neutron RT 
Personal Factors 
Age 
Disease Factors 
Diagnosis 
Staging 
Brain Stem Glioma 
Glioblastoma Multiforme 
Ependymoma 
Histologic Feature 
Histology Grade 
Clinical 
Duration of Symptoms 
Extent of Disease 
Performance Status 
Signs & Symptoms 
Treatment Factors 
Biopsy 
Outcome Factors 
Disease Control 
Response 
Toxicity 
Treatment Complications 
The concepts shown in Exhibits 19 and 20 help explain the selection process 
employed leading to RTOG-9305. Exhibit 19 indicates that surgery and conventional 
radiation therapy can be used for comparison purposes. Exhibit 20 indicates the need for 
an innovative approach using radiotherapy. The value of a conventional radiation therapy 
regimen may be seen by the studies showing quality of life measures, implying that 
patients have benefitted sufficiently to motivate investigation of survival quality. Finally, 
99 
Exhibit 15 supplies the information that the concept structure employing the combination 
of chemotherapy, surgery and radiation therapy modalities is not substantially different. 
One strategy which could be developed is that used in RTOG-9305-conventional 
treatment vs new radiotherapy plus conventional treatment. 
A protocol from the M.D. Anderson Cancer Center, MDA-DM-92035 
(Appendix C), illustrates a chemotherapeutic strategy. That protocol describes a 
randomized Phase III study of two chemotherapeutic regimens-PCB, CCNU, VCR vs 
DFMO plus PCB, CCNU, VCR. The underlying strategy illustrated in Exhibit 15 is 
effective utilization of surgery, radiation therapy and chemotherapy. Disease control 
parameters have a higher priority than do survival parameters because of the difficulties 
in shrinking tumors and in maintaining minimal size. However, difficulties in assessing 
reduction in size of tumors and in differentiating between viable tumor and the 
complications associated with debris from destroyed tumor have led to substitution of 
survival for traditional response parameters. As such, investigators would seek ways to 
combine the three modalities to accomplish the disease control objective while measuring 
effect by improved survival. 
MDA-DM-92035 illustrates two components of study design. The first is to 
enhance the effects of radiotherapy by employing a radiosensitizer; the one selected for 
this protocol is DFMO. The second is to increase chances of satisfactory disease control 
by choosing a multi-agent chemotherapy program. The ingredients in such regimens 
must minimize severe toxicities while subjecting the tumor cells to aggressive attack. 
The combination of procarbazine, lomustine, vincristine (PCB, CCNU, VCR (PCV)) had 
been studied in patients with recurrent disease and offered potential benefit in newly 
diagnosed patients. 
The patients selected represent those diagnoses with poorer prognosis but in whom 
DFMO and/or PCV had demonstrated some success (see Appendix D for more recent 
abstracts in 1992). The protocol required prior treatment with radiotherapy in order to 
test the anticipated interaction with DFMO. 
In understanding the selection process employed in developing this protocol, 
Exhibit 15 illustrates a strategy which requires enhancement of the use of the three 
modalities to improve outcome. Assuming that a multi-modality approach is effective, 
the focus of a new research program could be on improved surgical procedure, improved 
radiotherapy, or improved chemotherapy.4XMDA-DM-9203:nemonstrated investigator 
interest in enhancing the effects of radiotherapy by employing a radio sensitizer . The 
chemotherapy regimen chosen was one previously studied and found to be promising 
without undue toxicity. 
The protocol developed by the Brain Tumor Study Group, BTRC-6G901 (see 
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Appendix C), provides another example of the strategy from Exhibit 15. The emphasis 
in this protocol is on improving the delivery of the radiotherapy by employing 
hyperfractionation and DFMO. The protocol compares hyperfractionation with and 
without DFMO against single fraction RT with and without DFMO. As seen in Exhibit 
20, hyperfractionation is a newer form of radiotherapy. The question studied relates 
effective dose of radiation delivered to the tumor cells in enhancing survival. Under the 
conditions of the study, the best survival should be seen in patients receiving the 
combination of hyperfractionation plus DFMO. The poorest survival should be in the 
patients receiving single fraction RT without DFMO. 
Conceptual Display of Treatment Protocols 
The protocol descriptions from the PDQ system were analyzed and the ideas 
extracted which dealt with patient groups, disease factors, treatments, and outcome 
measures. Each of the protocol idea sets was computerized and used with the Inspiration 
software to develop concept structure displays. These concept structures are shown in 
Appendix A. Each display shows the variables associated with the following categories 
of terms: 
1. Personal factors; 
2. Disease factors; 
3. Treatment factors; 
4. Outcome factors. 
Figure 7 illustrates this organization. The treatments being considered were 
standard dose RT versus high dose RT. The personal factors were pregnancy and age 
of patient. The disease factors included measures of existing disease, diagnoses, and 
history of prior treatments. The outcome factors were relapse, survival and toxicity. 
This same detailing is associated with each of the displays in Appendix A. 
Figure 7 
Concept Structure of Standard vs High Dose RT 
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Figure 8 summarizes the frequency of terms in the treatment protocols and 
displays the terms in a concept structure. Three personal factor variables were featured. 
Age was present in 96% of the protocols; pregnancy was in 40% and lactation in 24%. 
Terms occurring less than 10 % of the time are not shown. 
Outcome factors involved toxicity measures in 84% of the protocols. Response 
or remission were included in 67% and survival in 70% of the protocols. Progression 
of disease was in 44% and response duration was in 20% of the protocols. 
Existing disease as a subdivision of disease factors included coronary disease 
(16%), AIDS (10%), infection (28%), in-situ cervical cancer (28%), and non-
melanomatous skin cancer (32 %). 
History of prior treatments included RT in 76% of the protocols, corticoids in 
26%, surgery in 58%, and chemotherapy in 72%. 
The diagnoses listed were oligodendroglioma in 46% of the protocols. Glioma 
was listed in 46 %, astrocytoma in 70 %, and glioblastoma multiforme in 42 % . 
Karnofsky performance score was used in 46 % of the protocols and life 
expectancy in 46 % . 
Laboratory values included alkaline phosphatase in 14%, AGC in 26%, Hb in 
22 %, bilirubin in 62 %, SGOT in 48 %, SGPT in 36 %, platelets in 66 %, BUN in 30 % , 
creatinine in 68 %, and WBC in 44 % . 
Figure 8 
Frequency of Terms in 50 Treatment Protocols 
Coronary 
Disease 16% 
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Figure 9 shows the frequency of treatments used in the protocols. The most 
frequently occurring form of treatment was chemotherapy alone. This was included in 
58% of the protocols. RT + chemotherapy was next, with 24% inclusion in protocols. 
The remaining treatment forms occurred less than 10% of the time. 
Figure 9 
Frequency of Treatments in 50 Protocols 
RTf 
CHEMOTHERAPY 
24% 
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PROTOCOLS 
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Figure 10 shows the frequency of terms in the brain tumor ideabase related to 
of outcome. The most frequently occurring form of treatment was 
; it was included in 86 % of the ideas linking treatment forms with outcome 
RT was next with 40% and biological therapy was included in 16% of the ideas 
with outcome. The others shown were in less than 10% of the ideas. 
Age and toxicities were the other high frequency terms employed in ideas linking 
outcome factors with other categories. Survival and astrocytoma were next in frequency 
occurring, respectively, 75% and 70% of the time. 
Sex, Karnofsky performance status, glioblastoma multiforme and glioma were 
in frequency, occurring in 40%-60% of the ideas linking outcome and other 
categories. 
The idea analysis methodology was illustrated using the scientific articles dealing 
with brain tumor management and treatment. The process involved comparing results 
of subject specialist actions in building new research protocols with that used in building 
idea-based concept structures. In addition, treatment protocols from the PDQ system 
were retrieved and analyzed. The ideas describing the management and treatment of the 
patients were extracted and computerized. These idea sets were then entered into the 
Inspiration software and concept structures developed. Summary graphs were 
constructed showing the frequency of inclusion of terms in the treatment protocols. A 
comparable graph was constructed showing the frequency of terms in the scientific 
literature. 
Comparing Figures 8 and 10 shows the close agreement between the term 
frequencies. The identification of high frequency terms from the literature, such as age, 
toxicities, survival, response/relapse, astrocytoma, and chemotherapy, raises the question 
of their importance in consideration of brain tumor and its management. The high 
frequency terms from the new protocols were: age, toxicities, survival, 
response/remission, astrocytoma, and chemotherapy. The two lists agree. It is of 
interest that the literature list (Figure 10) came from a formalized analysis of the 
literature and was restricted only to those ideas exhibited in the form of tables and 
graphs. The second list (Figure 8) came from the subject experts and involved their 
knowledge of the same literature plus all of the related literature. In addition, the subject 
experts' purview of the literature is not restricted to the data displays but takes in all of 
the information present. 
Figure 10 
Frequency of Terms in the Brain Tumor Ideabase Related To Outcome 
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Chapter V 
Discussion 
Introduction 
A methodology called Idea Analysis was investigated to determine its ability to 
accomplish the organization of the information such that the results of the specialists' 
deliberations in designing new clinical trials could be explained. 
This methodology focuses on the ideas presented in the scientific literature. With 
this methodology, identification, extraction, computerization and incorporation of new 
ideas into existing knowledge structures can be accomplished in an efficient and effective 
. manner. If Idea Analysis were successful in accomplishing the purposes in this research, 
the procedures could be considered as satisfying two important issues in information 
processing: 
1. The processing of large amounts of information, such that the new 
are integrated with the existing in continuously updated concept 
structures; 
2. The duplication of subject specialists' results in the development 
of new clinical research studies. 
Ideas have long been recognized as the engine of creativity. By focusing on the 
capture of ideas from the scientific literature, idea analysis procedures enable the 
organization of the information into forms consistent with those from subject specialists. 
The most obvious example of that is the concept structure. Ideas containing a common 
term/phrase can be depicted as a node in the concept network. The common term/phrase 
can be considered as the primary node and the related terms as elements associated with 
that node. Ideas containing couplets of primary nodal terms/phrases provide the 
wherewithal to link nodes to complete the paths in the network. This process can be 
performed by individuals trained in information processing rather than in the specific 
subject of interest. In this fashion, information specialists can form and maintain 
knowledge structures for use by students, specialists and interested others. 
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The advantage of such structures is the savings in time, money and energy now 
expended in repetitive analyses of the same literature. Literally thousands of individuals 
around the world can be working simultaneously and independently on the same subject 
and even on the same topics within the subject. This duplication of effort is deleterious 
to advancement of knowledge, in that the basic data extracted are never shared or 
organized as knowledge resources. The identification and extraction of ideas by the 
individuals involved is a transitory task. The procedures used are mainly clerical in 
nature. When these clerical functions are performed manually, the fatigue factor cannot 
be discounted. As such, the individual investigator is hampered in accomplishing desired 
objectives. 
The belief that creativity must be preceded by enormous amounts of fatigue and 
frustration may be a concession to manual processing techniques. With the introduction 
of computer technology, the manual procedures involved in identifying, extracting, 
copying, sorting, merging, and appending ideas can be performed without human 
intervention, once the rules of processing have been defined. This lesson from 
artificial intelligence has been amply demonstrated. 
Clinical Trials 
Clinical investigation has been perceived as a form of creative scientific behavior. 
The methodology involved is called clinical trial research. The clinical investigation 
differs from other forms of research, in that two equally important objectives are 
considered. The first is the provision of best available care to patients with specific 
disease characteristics. The second is the acquisition of new information which will 
enhance understanding of the disease process and its management. The development of 
this important form of investigation in medical science has required the expertise and 
skill of persons knowledgeable in the various branches of medicine and in the 
methodology essential to the acquisition of new therapeutic information. 
Clinical trials are developed when standard treatments fail to cure or control 
disease. The new information provided by the clinical trial mechanism is intended to 
improve the quality of care. The development of clinical trials is a sophisticated process 
involving the contributions of many different investigators, each specializing in different 
diagnostic and therapeutic modalities (Carter, 1985; Cheson, 1991; Pocock, 1983). 
These investigators bring to the planning process their individual bodies of knowledge 
and, through group interaction, evolve a strategy for a therapeutic approach, a treatment 
plan, and a design for a clinical trial. This development process may require months to 
years of discussion and information exchange. The time is spent overcoming sources of 
confusion and obfuscation. The various disciplines represented contribute to the 
developmental time by describing commonly accepted concepts using different languages 
and by masking concepts intuitively evident to one discipline but not to all. This process 
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is a modem version of the 'Tower of Babel' effect (Mikhailov et al., 1984, pp. 25-26). 
Since the number of published scientific articles has been exponentially increasing 
over the past years, information processing methods employed in bringing new 
information to the clinical trial design capability should facilitate continuous integration 
of new with existing information. Information processing methods are needed that 
reproduce the results of the creative process used by scientists. Ideally, such methods 
should reduce the time and effort needed to design protocols. 
A primary problem facing researchers is the sheer volume of literature to be 
considered. The ten thousand scientific and technical journals now published increase 
by six to seven percent a year (de Solla Price, 1981). This increase in the literature is 
reflected in a policy change by the National Library of Medicine from a monthly update 
of the MEDLINE database to a semi-monthly update schedule ("MEDLINE moving," 
1988). Gabrieli et al. (1985) stated that a practitioner should read 657 articles per day, 
including Saturday and Sunday, to stay current. Most physicians spend a few hours a 
day reading and have a set time for reviewing journals (H. J. Bennett, 1992; Manning 
& DeBakey, pp. 31-56). Many books and articles have been written on how to keep up 
with the literature (Gehlbach, 1993; Haynes et aI, 1986a, 1986b, 1986c, 1986d, 1986e, 
1986f; Riegelman, 1981). 
In addition to volume, there is the problem of an increasing number of journals 
in specialty areas (Datta, 1987; Sengupta & Wyatt, 1987; Todd, 1967). Related to this 
problem is the one of identifying the journals where the information may be found. 
Depending on the target group, the authors of an article may publish their results in 
general medical journals such as the New England Journal of Medicine; general subject 
journals such as Cancer; or in a discipline specific journal such as Gynecological 
Oncology (Dunn, 1981; J. M. Weiner, Shirley, et aI., 1981). This dispersal of the 
information requires researchers to spend even more time and money locating all 
pertinent information. 
Other sources of information for researchers include: the invisible college, 
textbooks, scientific meetings, and workshops (Crane, 1969; Manning & DeBakey, pp. 
81-100; Osiobe, 1985; A. D. Weinberg et aI., 1981). For researchers in cooperative 
groups, the unpublished data of recently completed studies and preliminary analyses of 
current trials provide additional information (Malogolowkin et al., 1989). 
A second obstacle in clinical trial design is obtaining consensus among the experts 
regarding what information should be used (Bernstein et aI., 1980; Giuse et aI., 1993; 
Rossi-Mori & Steve, 1985, Shaw & Gaines, 1989). One aspect to be considered is the 
need to separate the ideas from the data. Many ideas may be rejected because the author 
or institution is not well known, the methodology appears flawed, or because of some 
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other unspecified bias (Peters & Ceci, 1982; Suarez & Lemoine, 1986). The rejection 
of these ideas contributes to the delay in developing clinical trial strategies. 
Clinical Trial Model 
This dissertation describes the investigation of an information processing approach 
intended to duplicate the research strategies developed by experts by demonstrating 
rationales for the final results of clinical trial research plans/strategies by experts. The 
ideas employed were restricted to the set derived from numerical relationship displays. 
Those ideas were organized using an algorithm to form descriptions of clinical trial 
research strategies. These strategies, in turn, were used in a comparison with those 
developed by the subject experts. 
are: 
The algorithm is used to categorize the terms in ideas into five groups. These 
1. Environmental factors, such as climate, geography, and institution; 
2. Personal factors, such as age, gender, and income; 
3. Disease factors, such as blood pressure, fever, or extent of disease; 
4. Treatment factors, such as surgery, chemotherapy, or radiation 
therapy; 
5. Outcome factors. There are four classes: survival, disease control, 
toxicities, quality of life. 
Numerous terms could be placed correctly into more than one category. In 
keyword applications, such classification of single terms/phrases would be difficult 
because the authors' intended meaning of the word(s) would not be evident. 
The couplet of terms (i.e., the idea) offers increased understanding of the content 
of the document compared with separately displayed keywords or phrases. For example, 
a couplet describing a relationship between treatment and survival clearly shows that the 
author considered (and probably studied) the relationship(s) between treatment and 
survival. 
The individual terms do not provide the same understandings. Individually, 
treatment or survival suggest that the author considered those terms but there is no 
indication as to how or for what purpose. With the couplet of terms as a single entity, 
it is easier to combine that thought with others to form a concept. A concept is defined 
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as a set of thoughts which form a description of a component in a topic (Sharkey, 1986; 
Soergel, 1985). Another way to think of a concept is a mental construct and unit of 
thought used to structure knowledge and to perceive the surrounding world. A system 
of concepts/terms provides a mental ordering of knowledge to visualize and clarify 
relationships between concepts/terms. 
Even retrieval is made more accurate and efficient. Articles dealing with the 
individual terms are eliminated from consideration. Only those in which the authors 
linked the terms involved are included. Boolean combinations cannot match that clarity 
of understanding (Cooper, 1988; B. H. Weinberg, 1988). 
Classification of couplets of terms by the algorithm is simplified. The couplet 
describes an idea and the idea conveys the thought intended by the authors. As examples 
of the contrast, consider terms such as response and responder. If considered as separate 
words, the most likely category would be outcome factors. When each term is coupled 
with its related term, the classification becomes clearer. Consider response-treatment and 
responder-treatment. The first couplet would be consistent with the author's intent to 
treat and achieve a measure of disease control. The treatment would be classified in the 
treatment factors category and the response would be classified as an outcome factor. 
The second couplet would be consistent with the selection of individuals with a history 
of response to prior treatment and the choice of subsequent treatment in accordance with 
that prior history. The term 'responder' would be considered as a disease factor. The 
term 'treatment' would be classified as a treatment factor. 
The clinical trial design model states that patient groups are defined by 
environmental, personal and disease factors. Given patient subgroups, treatments are 
selected to best accomplish the measure of outcome chosen as most pertinent. By 
organizing the ideas according to the model, possible descriptions of clinical trials could 
be revealed. 
Analysis of the scientific literature using techniques and concepts from idea 
analysis is based on the premise that specific information processing techniques may be 
applied in a formalized algorithmic fashion. Further, this analytic process will provide 
results which match those from specialists in the subject (J. M. Weiner & Horowitz, 
1992; J. M. Weiner, Horowitz, & Latinwo, 1987). The process involved does not 
attempt to duplicate any procedure performed by subject specialists. Instead, the idea 
analysis process is focused on the management of ideas and the arrangement of those 
ideas using organizational models. 
The application of these techniques to the scientific literature dealing with brain 
tumors is illustrative. The purpose of the analysis was to identify the possible strategies 
which might be used in constructing new clinical trial protocols. The strategies formed 
were compared with those used in actual protocols developed by clinical investigators. 
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Concept Structures and Clinical Trial Protocols 
The development of concept structures was illustrated in tabular (e.g., Exhibit 15) 
and graphic (e.g., Figure 8) forms. Exhibit 15 showed the chemotherapy-survival related 
ideas from the brain tumor literature. The linkages between the principal term/phrase 
at the top of the display-survival-and the terms/phrases related to that principal 
term/phrase were given in this exhibit. The outline format showed the major 
terms/phrases, i.e., primary nodes, and the terms linked with them. In this way, the 
outline depicted a concept structure. 
A major advantage from the idea analysis approach lies in the ability to depict a 
particular course of action or research strategy adopted by investigators when they build 
a new research protocol. This was illustrated by the data shown in Exhibit 16. That 
display showed the ideas from Exhibit 15 used in building protocol RTOG-9305, a 
clinical trial initiated by the Radiation Therapy Oncology Group (RTOG). 
By comparing Exhibits 15, 16 and 17, the focusing performed by the subject 
specialist was illustrated. The specialist selected the elements of interest from the 
scientific literature and added new data as required. The new element added in the 
RTOG protocol was the stereotactic· radiosurgery, a form of carefully controlled, narrow 
beam radiation using various energy forms. The conceptual structure as viewed by 
considering chemotherapy (Exhibit 15) identified type of RT as an important component 
of treatment. The emphasis on surgery, chemotherapy or radiotherapy could be expected 
to depend on the interests and training of the subject specialists. Being a radiotherapy-
oriented clinical trial organization, the RTOG focused their attention on newer 
radiotherapeutic approaches. The choice of BeNU as the chemotherapeutic agent 
represented a desire for a standard "control." Similarly, combining BeNU with 
conventional RT, another standard "control," provided a comparison regimen for the new 
combination regimen employing radiosurgery and BeNU. If radiosurgery were effective 
in reducing inoperable tumors, the combination employing that regimen could show 
increased survival because of better disease control. The randomized Phase III study 
design chosen is best suited to provide that information. 
The concepts shown in Exhibits 19 and 20 helped explain the selection process 
employed leading to RTOG-9305. Exhibit 20 indicated the need for an innovative 
approach using radiotherapy. Exhibit 19 indicated that surgery and conventional 
radiation therapy could be used for comparison purposes. The value of a conventional 
radiation therapy regimen could be seen by the studies showing quality of life measures 
implying that patients have benefitted sufficiently to motivate investigation of survival 
quality. One strategy which could be developed from the data shown was that used in 
RTOG-9305-conventional treatment vs new radiotherapy plus conventional treatment. 
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A protocol from the M.D. Anderson Cancer Center, MDA-DM-92035, illustrated 
a chemotherapeutic strategy. That protocol described a randomized Phase III study of 
two chemotherapeutic regimens-PCB, CCNU, VCR vs DFMO plus PCB, CCNU, 
VCR. The underlying strategy illustrated in Exhibit 15 was the effective utilization of 
surgery, radiation therapy and chemotherapy. MDA-DM-92035 illustrated two 
components of study design. The first was to enhance the effects of radiotherapy by 
employing a radiosensitizer; the one selected for this protocol is DFMO. The second 
was to increase chances of satisfactory disease control by choosing a muli-agent 
chemotherapy program. The combination of procarbazine, lomustine, and vincristine 
(PCB, CCNU, VCR (PCV», had been studied in patients with recurrent disease and 
offered potential benefit in newly diagnosed patients. The patients selected represent 
those diagnosed with poorer prognosis but in whom DFMO and/or PCV had 
demonstrated some success. 
In understanding the selection process employed in developing this protocol, 
Exhibit 15, illustrated a strategy which required enhancement of the use of the three 
modalities to improve outcome. Assuming that a multi-modality approach was effective, 
the focus of a new research program could be on improved surgical procedure, improved 
radiotherapy, or improved chemotherapy. MDA-DM-92035 demonstrated investigator 
interest in enhancing the effects of radiotherapy by employing a radiosensitizer. The 
chemotherapy regimen chosen was one previously studied and found to be promising 
without undue toxicity. 
The protocol developed by the Brain Tumor Study Group, BTSC-6G901, provided 
another example of the strategy from Exhibit 15. The emphasis in this protocol was on 
improving the delivery of the radiotherapy by employing hyperfractionation and DFMO. 
The protocol compared hyperfractionation with and without DFMO against single fraction 
RT with and without DFMO. As seen in Exhibit 20, hyperfractionation was a newer 
form of radiotherapy. The question studied dealt with effective dose of radiation 
delivered to the tumor cells in enhancing survival. Under the conditions of the study, 
the best survival would be seen in patients receiving the combination of 
hyperfractionation plus DFMO. The poorest survival should be in the patients receiving 
single fraction RT without DFMO. 
Appendix A shows concept structures for fifty protocols from the PDQ system. 
Each of these protocols was developed by subject specialists and each protocol was 
subjected to peer review prior to being approved for study. The peer review at the 
national level involved committees of consultants to the National Cancer Institute (NCI). 
A similar process at the local institutional level involved investigators and interested 
others. The latter process is required by law for the protection of patients' well-being. 
The ideas involving patient management and treatment were extracted from the 
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protocols and used to construct the individual concept structures as well as a summary 
structure. The frequencies of terms involved in the ideas were determined and the high 
frequency terms were shown in Figures 8 and 9. Figure 10 showed the frequency of 
terms in the brain tumor ideabase related to measures of outcome. 
Comparing Figures 8 and 10 showed the close agreement between the term 
frequencies. The identification of high frequency terms from the literature, such as age, 
toxicities, survival, response/relapse, astrocytoma, and chemotherapy, raised the question 
of their importance in consideration of brain tumor and its management. The high 
frequency terms from the protocols were: age, toxicities, survival, response/remission, 
astrocytoma, and chemotherapy. The two lists agreed. It is of interest that the literature 
list (Figure 10) came from a formalized analysis of the literature and was restricted only 
to those ideas exhibited in the form of tables and graphs. The second list (Figure 8) 
came from the subject experts and involved their knowledge of the same literature plus 
all of the related literature. In addition, the subject experts' purview of the literature is 
not restricted to the data displays but takes in all of the information present. 
Potential Limitations 
There were a number of limitations in the study process. First, the comparison 
to be made involved ideas from the literature versus those from clinical trial protocols. 
The data sets leading to the two concept structures were not comparable, in that the 
literature provided original findings and the protocols provided expert-filtered and 
summarized findings. 
A second limitation dealt with the fact that the subject specialist process and the 
computer algorithm have different supporting databases. Investigators designing clinical 
trial protocols have access to all of the world's literature including laboratory, 
pre-clinical and clinical information. They also have access to pre-published information 
via contacts with colleagues. The ideabases were limited to clinical literature and only 
to those articles containing numeric displays. 
The third limitation was the focus on clinical trials of treatments for patients with 
brain tumors. While there is no a priori reason to expect clinical trials of brain tumor 
to be different from those found in other diseases, that premise is assumed rather than 
tested in this study. 
The fact that the literature and the protocols contained a common set of high 
frequency terms could be viewed as simply the background structure of concepts making 
up management and treatment of brain tumors. That is, the agreement in the content of 
the lists does not explain specialist action but simply describes the subject in a general 
way. Assuming the correctness of that argument, what would be the value of having a 
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formalized process for identifying, extracting, computerizing, and organizing ideas? 
Would there be value derived from the rapid and accurate formation of concept structures 
describing complex subjects? 
The premise inherent in idea analysis is that descriptions of complex subjects can 
be developed without prior knowledge of and expertise in that subject. By following a 
defined algorithm for the organization of the information, the ideas involved in the 
description can be retrieved and entered into a conceptual network. That concept 
structure duplicates the descriptions provided by subject specialists. The existence of a 
formalized procedure which provides such information could be considered of value in 
education. 
The analysis of brain tumor literature and protocols showed that the experts' 
actions in forming new clinical trial research could be described with respect to final 
results. While these descriptions did not intend to explain the experts' thought-patterns, 
these descriptions did provide an explanation of the information selection and 
organizational process leading to the same results as those provided by the experts. Idea 
analysis, in contrast to artificial intelligence and expert systems, does not attempt to 
duplicate experts' creative behavior. Instead, it attempts to duplicate the results of the 
experts' creative process. 
As such, the fact that there was agreement between two lists of high frequency 
terms, one from the literature and one from the clinical trial protocols, suggests that idea 
analysis can accomplish its intended purposes. The idea analysis methodology enabled 
the formation of a formalized process. This formalization established procedures and 
roles which could be performed by individuals with training in those behaviors apart 
from the subjects involved. This capability is central to information processing. By 
separating the roles performed most efficiently and expeditiously by the computer, by 
trained technicians, and by subject specialists, the construction and maintenance of 
knowledge bases is realistic and feasible. Further, the constructed knowledge bases can 
be used by all concerned with the subject, without the wasteful and redundant 
reconstruction process now employed in manual analysis of the literature. 
Summary 
Idea analysis represents a new approach to the analysis of the scientific literature 
and to the use of the information obtained. An important difference when compared with 
existing online information systems is the emphasis placed on the use of the information. 
The end result of the process is a description of existing knowledge using graphic or 
tabular displays of the concepts studied in the subject. This organization of ideas to form 
representations of concept structures is a major breakthrough in providing cognitive tools 
to the specialist, the student and interested others. 
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This study showed that, in the brain tumor literature and clinical trial protocols, 
the idea analysis approach was effective in accomplishing the two tasks required: 
1. Organization of complex material into succinct and understandable 
descriptions-tabular and graphic; 
2. Provision of explanations of expert-derived research strategies 
and/or plans. The idea analysis procedures focus on identifying, 
extracting, computerizing, and organizing ideas from the scientific 
literature. This emphasis on ideas simplifies the development of 
organizations of the informational data because of the existence of 
common terms/phrases in the couplets of terms/phrases making up 
ideas. The common terms/phrases in the idea couplets are 
comparable to primary nodes in a conceptual network. These 
terms and their related ones form nodes in the complete complex 
structure making up a conceptual network for a subject. 
The complete concept structure available from analysis of the ideas provides a 
background against which each protocol can be considered. By superimposing the 
protocol onto this background, the particular focus chosen by the specialists can be seen. 
As such, an explanation of the final result of their creative action, i.e., the protocol, can 
be developed. The formalized procedures used in developing the description represent 
a potentially valuable asset in information processing. 
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Appendix C 
RTOG-9305 
MDA-DM-92035 
BTRC-6G901 
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RTOG-9305 
Phase III Study of Radiosurgery Followed by Conventional Radiotherapy with BCNU vs 
Conventional Radiotherapy with BCNU in Patients with Supratentorial Glioblastoma 
Multiforme (Summary Last Modifed 02/94) 
PROTOCOL STATUS = Approved - Not yet active 
James D. Cox 
University of Texas - M.D. Anderson Cancer Center 
1515 Holcombe Boulevard 
Houston, TX 77030-4095 
713-792-2260 
Lead Organization 
Radiation Therapy Oncology Group 
Philadelphia P A 
ACCEPTABLE AGE RANGE: 18 and over 
OBJECTIVES: 
I. Determine whether the use of radiosurgery (stereotacticexternal-beam 
irradiation) prior to conventional radiotherapy with carmustine (BCNU) 
improves overall survival compared to conventional radiotherapy plus BCNU 
alone in patients with supratentorial glioblastoma multiforme. 
II. Determine and compare the frequency and severity of toxicities associated 
with these regimens. 
III. Compare the effects of these two regimens on neurologic function and 
quality of life. 
PROTOCOL ENTRY CRITERIA: 
--Disease Characteristics--
Histopathologically confirmed supratentorial glioblastoma 
multiforme 
Diagnosis by surgical biopsy or resection required 
RTOG-9305-Continued 
The following tumor types are specifically excluded: 
Astrocytoma with atypical or anaplastic features 
Well differentiated astrocytomas 
Tumors originating in the brain stern 
Tumors located within 5 rnrn of the optic chiasm 
Infratentorial tumors 
Multifocal malignant glioma 
Recurrent malignant glioma 
257 
Well circumscribed contrast-enhancing tumor on pre- and postoperative contrast -enhanced 
CT or MRI with a maximum diameter (in any direction) of 40 rnrn required 
Tumors that do not enhance on postoperative CT or MRI excluded 
--Prior/Concurrent Therapy--
Biologic therapy: 
Not specified 
Chemotherapy: 
No prior chemotherapy 
Endocrine therapy: 
Not specified 
Radiotherapy: 
No prior radiotherapy to the head and neck 
Surgery: 
No more than 4 weeks since surgery 
Recovered from effects of surgery and any postoperative complications 
--Patient Characteristics--
Age: 
18 and over 
Performance status: 
Karnofsky 60-100 % 
RTOG-9305-Continued 
Life expectancy: 
At least 3 months 
Hematopoietic: 
ANC at least 1,500 
Platelets at least 100,000 
Hb at least 10 g/dl (may transfuse) 
Hepatic: 
Bilirubin no greater than 2.0 mg/dl 
SGOT or SGPT no greater than 2 x normal 
Renal: 
Creatinine no greater than 1.5 mg/ dl 
BUN no greater than 25 mg/dl 
Pulmonary: 
Chest x-ray normal 
If abnormal or if there is a history of pulmonary disease, pulmonary function 
studies (including DLCO) must be at least 75% of predicted 
Other: 
Neurologic function status 0-3 
No AIDS 
No major medical or psychiatric illness that would preclude protocol therapy 
or follow-up 
No second malignancy within 5 years except: 
N onmelanomatous skin cancer 
In situ carcinoma of the uterine cervix 
PROTOCOL OUTLINE: 
Randomized study. 
Arm I: 
Arm II: 
Radiotherapy plus Single-Agent Chemotherapy. Tumor irradiation 
using megavoltage equipment (at least 4 MV photons); plus 
Carmustine, BCNU, NSC-409962. 
Radiosurgery followed by Radiotherapy plus Single-Agent 
Chemotherapy. Stereotactic tumor irradiation; followed by tumor 
irradiation as in Arm I; plus BCNU. 
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RTOG-9305-Continued 
STRATIFICATION BY: 
Age (under 50 vs. 50 and over), Karnofsky perfonnance status (60-80 vs. 90-100), 
participating institution. 
END POINTS: 
Survival, toxicity/morbidity of treatment, mental function, quality of life. 
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MDA-DM-92035 
Phase III Randomized Trial of PCV (PCB/CCNU/VCR) with vs without DFMO in 
Patients with Malignant Gliomas Who Have Received Radiotherapy (Summary Last 
Modified 03/94) 
PROTOCOL STATUS = Active 
Victor Alan Levin 
University of Texas - M.D. Anderson Cancer Center 
Hospital Box 100 
1515 Holcombe Boulevard 
Houston, TX 77030 
713-792-8287 
Lead Organization 
University of Texas - M.D. Anderson Cancer Center 
Houston TX 
ACCEPTABLE AGE RANGE: 16 and over 
OBJECTIVES: 
I. Compare, in a randomized Phase III study, the survival of patients with malignant 
glioma previously treated with radiotherapy who are treated with eflornithine plus 
procarbazine/lomustine/vincristine (PCV) vs. PCValone. 
PROTOCOL ENTRY CRITERIA: 
--Disease Characteristics--
Histologically confirmed malignant glioma of one of the 
following types: 
Glioblastoma multiforme 
Gliosarcoma 
Anaplastic astrocytoma 
Malignant oligodendroglioma 
Mixed malignant glioma 
--Prior/Concurrent Therapy--
Biologic therapy: 
Not specified 
MDA-DM-92035-Continued 
Chemotherapy: 
No prior chemotherapy except hydroxyurea during radiotherapy 
At least 2 weeks since hydroxyurea 
Endocrine therapy: 
Not specified 
Radiotherapy: 
Prior radiotherapy required 
No more than 4 weeks since radiotherapy 
Surgery: 
Not specified 
--Patient Characteristics--
Age: 
16 and over 
Performance status: 
Karnofsky 70-100% 
Life expectancy: 
More than 8 weeks 
Hematopoietic : 
ANC greater than 1,500 
Platelets greater than 125,000 
Hepatic: 
Bilirubin less than 1.5 x normal 
SGPT less than 2 x normal 
Alkaline phosphatase less than 2 x normal 
Renal: 
Creatinine less than 1.5 x normal 
Other: 
No active infection 
No major organ dysfunction that may obscure toxicity or alter 
DFMO pharmacokinetics 
No other serious intercurrent illness 
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MDA-DM-92035-Continued 
No pregnant women 
Adequate contraception required of fertile women 
PROTOCOL OUTLINE: 
Randomized study. 
Arm A: 3-Drug Combination Chemotherapy with Chemosensitization. PCV: (PCB, 
CCNU, VCR), DFMO. 
ArmB: 3-Drug Combination Chemotherapy. PCV. 
STRATIFICATION BY: 
Tumor histology (glioblastoma multiforme and gliosarcoma vs. anaplastic astrocytoma), 
participating institution. 
END POINTS: 
Survival, responseiremission rate, time to progression, toxicity/morbidity of treatment. 
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BTRC-6G901 
Phase III Trial of Accelerated Hyperfractionation with or without DFMO vs Single 
Fraction Radiotherapy with or without DFMO in Patients with Newly Diagnosed 
Glioblastoma Multiforme (Summary Last Modified 02/92) 
PROTOCOL STATUS = Active 
Michael Del Prados 
Neuro-Oncology Service 
University of California, San Francisco 
Suite 805 
350 Parnassus Avenue 
San Francisco, CA 94117 
415-476-2966 
Lead Organization 
Brain Tumor Research Center 
San Francisco CA 
ACCEPTABLE AGE RANGE: over 18 
OBJECTIVES: 
1. Evaluate survival time, response rates, time to tumor progression, and acute and 
late toxicities in patients with newly diagnosed glioblastoma multi forme 
randomized to either standard radiotherapy with vs. without eflornithine (DFMO) 
radio sensitization or accelerated hyperfractionated radiotherapy with vs. without 
eflornithine radio sensitization. 
PROTOCOL ENTRY CRITERIA: 
--Disease Characteristics--
Primary, newly diagnosed, intracranial glioblastoma multiforme 
Ineligible for protocols BTRC-6G902 (interstitial 
radiotherapy with vs. without hyperthermia) and NCOG-6G872 
(neon radiotherapy) 
Patients who refuse entry to protocol NCOG-6G872 may be 
eligible, at the discretion of the protocol chairman, for 
this protocol 
Glioblastoma of the spinal cord or brain stem excluded 
BTRC-6G901-Continued 
Therapy should begin within 4 weeks of surgery (admission 
after 4 weeks permitted, but patients will be analyzed 
separately) 
--Prior/Concurrent Therapy--
Biologic therapy: 
Not specified 
Chemotherapy: 
No prior chemotherapy 
Endocrine therapy: 
Steroids allowed (must be documented) 
Radiotherapy: 
No prior radiotherapy 
Surgery: 
Prior surgery permitted 
--Patient Characteristics--
Age: 
Over 18 
Performance status: 
Kamofsky 60-100 % 
Life expectancy: 
At least 2 months 
Hematopoietic: 
WBC at least 3,000 
Platelets at least 100,000 
Hepatic: 
Not specified 
Renal: 
Not specified 
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BTRC-6G901-Continued 
Other: 
No major medical or psychiatric illness that would prevent 
administration or completion of therapy 
No pregnant women 
Scans/x-rays to document disease must be completed within 3 
weeks prior to randomization; chemistry/hematology must be 
completed within 2 weeks prior to randomization 
PROTOCOL OUTLINE: 
Randomized study. 
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Arm I: Radiotherapy. Tumor irradiation using megavoltage equipment with 
energies from 4 to 20 MV. Accelerated hyperfractionation. 
Arm II: 
Arm III: 
Arm IV: 
Radiotherapy with Radiosensitization. Tumor irradiation using equipment 
as in Arm I; with DFMO. Accelerated hyperfractionation. 
Radiotherapy. Tumor irradiation using equipment as in Arm I. Standard 
fractionation. 
Radiotherapy with Radiosensitization. Tumor irradiation using 
equipment as in Arm I; with DFMO. Standard fractionation. 
STRATIFICATION BY: 
Participating institution, Karnofsky performance status (60-80 % vs. 90-100 % ), age (less 
than 40 vs. 40-49 vs. 50-59 vs. 60 years and over), interval between surgery and 
radiotherapy (4 weeks or less vs. greater than 4 weeks), maximum tumor dimension on 
MRI scan (less than 4.0 cm vs. 4.0-5.9 cm vs. 6.0-8.0 cm vs. greater than 8.0 cm), 
extent of surgery (biopsy only vs. subtotal resection vs. total resection), eligible for 1-125 
brachytherapy (yes vs. no). 
END POINTS: 
Time to recurrence or progression, survival, response/remission rate, neurologic 
performance, steroid dependency, toxicity/morbidity of treatment. 
Appendix D 
References Describing DFMO or PCB, CCNU, VCR (PCV) 
(Source - Medline) 
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References Describing DFMO or PCB, CCNU, VCR (PCV) 
(Source - Medline) 
TI: Aggressive oligodendroglioma: a chemosensitive tumor. 
AU: Caimcross-JG; Macdonald-DR; Ramsay-DA 
SO: Neurosurgery. 1992 JuI; 31(1): 78-82 
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AB: Aggressive oligodendrogliomas, tumors that are symptomatic, enlarging, enhancing, 
and usually but not always anaplastic, respond to chemotherapy. We have observed 
responses to chemotherapy in 18 of 19 consecutively treated patients with newly 
diagnosed or recurrent aggressive oligodendrogliomas. A regimen of procarbazine, 
CCNU (lomustine), and vincristine (PCV) is predictably effective, but other drugs have 
antioligodendroglioma activity. Cooperative group trials will be necessary to determine 
the most effective drug, or combination of drugs, and to explore fully the role of 
chemotherapy in the treatment of this uncommon glioma. 
TI: Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and 
vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. 
AU: Jeremic-B; Jovanovic-D; Djuric-U; Jevremovic-S; Mijatovic-U 
SO: J-Chemother. 1992 Apr; 4(2): 123-6 
AB: Between 1981 and 1987, 133 patients with anaplastic astrocytoma (AA) or 
glioblastoma multiforme (GBM) were treated with surgery and post-operative 
radiotherapy. 36 AA and 31 GBM patients were treated with adjuvant chemotherapy 
consisting of CCNU 100 mg/m2 day 1, procarbazine 60 mg/m2 days 1-14, and 
vincristine 1.4 mg/m2 (max. 2 mg) days 1 and 8, every 6 weeks which we called a 
"modified PCV" (mPCV) regimen. 37 AA and 29 GBM patients were treated with 
adjuvant chemotherapy consisting of VM-26 75 mg/m2 days 1 and 2, and CCNU 60 
mg/m2 days 3 and 4, every 6 weeks. Prognostic covariates such as patient's age, 
Kamofsky performance status score and the extent of surgery were balanced between the 
two treatment groups. The time to tumor progression and survival time for both regimens 
show that mPCV produces a two-fold increase in these factors at the 50th and 25th 
percentile for AA patients, but not for GBM patients, although there are more long-term 
GBM survivors with mPCV than with the VM-26 + CCNU regimen. 
TI: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with 
PCV chemotherapy. 
AU: Glass-J; Hochberg-FH; Gruber-ML; Louis-DN; Smith-D; Rattner-B 
SO: J-Neurosurg. 1992 May; 76(5): 741-5 
AB: Malignant oligodendrogliomas have been shown to be responsive to chemotherapy. 
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The authors administered systemic chemotherapy to seven patients with oligodendroglioma 
or anaplastic oligodendroglioma, and to 14 with mixed oligodendroglioma-astrocytoma. 
Fourteen patients underwent chemotherapy before and seven after irradiation. The PCV 
(procarbazine, methyl-l-(2-chloroethyl)-1-nitrosourea (CCNU), and vincristine) 
chemotherapy was administered every 6 weeks (42-day cycles) for two to five cycles as 
follows: CCNU, 110 mg/sq m on Day 1; procarbazine, 60 mg/sq m/day on Days 8 to 21; 
and vincristine, 1.4 mg/sq m/day on Days 8 and 29. Complete or partial (greater than 50% 
reduction in tumor mass) responses at 20 to 100 + weeks after treatment were noted in 11 
(79 %) of the 14 patients treated before irradiation, including two with anaplastic 
oligodendroglioma and nine with mixed tumors. Complete responses were seen in two 
patients, one with anaplastic oligodendroglioma and one with a mixed tumor. Partial 
responses were seen in three of seven patients treated after radiotherapy. Stabilization of 
tumor growth followed PCV chemotherapy in four patients (two treated before and two 
after radiotherapy). Tumor growth progressed in two patients during therapy despite an 
initial response and in two patients despite therapy. The authors conclude that mixed 
oligodendroglial tumors as well as anaplastic oligodendrogliomas are responsive to PCV 
chemotherapy. 
TI: Treatment of recurrent gliomas with eflornithine. 
AU: Levin-VA; Prados-MD; Yung-WK; Gleason-MJ; Ictech-S; Malec-M 
SO: J-Natl-Cancer-Inst. 1992 Sep 16; 84(18): 1432-7 
AB: BACKGROUND: Oral eflornithine in combination with intravenous mitoguazone 
(methylbisguanylhydrazone) has shown activity against recurrent anaplastic gliomas. 
Eflornithine alone, however, has not been evaluated against recurrent gliomas. PURPOSE: 
This study compared the antitumor activity of oral eflornithine with that of oral 
eflornithine combined with intravenous mitoguazone in the treatment of patients with 
recurrent or progressive glioblastoma multiforme as well as nonglioblastoma anaplastic 
gliomas. METHODS: During the 1st year of therapy with eflornithine alone, the drug was 
given at a dose of 3.6 g/m2 on days 1-14, 22-35, and 43-56 every 8 hours; cycles were 
repeated every 63 days until progression. For the 2nd year, the drug was given on days 
1-14, 29-42, and 57-70, with 84 days between cycles. For the 1st and 2nd 
years of eflornithine-mitoguazone therapy, eflornithine was given at 1.8 g/m2 on the same 
schedule. Mitoguazone was given intravenously at 200 mg/m2 on the final day of each 
2-week sequence of eflornithine therapy. Response was determined by evaluating changes 
in the size of contrast-enhanced neuroimages. RESULTS: Because of two cases oflethal 
hepatic necrosis, the initial random allocation of patients to the eflornithine-mitoguazone 
arm was stopped after 23 patients had been accrued. Ninety-eight patients were entered 
in the eflornithine arm; 80 patients (36 glioblastoma multiforme patients and 44 anaplastic 
glioma patients) were assessable for response. Antitumor activity (partial response, minor 
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response, and stable disease) was seen in 45 % of the patients with anaplastic gliomas, fora 
median of 49 weeks, but in only 17 % of patients with glioblastoma multiforme (median 
not attained). Twenty-one (20%) of the patients with anaplastic glioma and 33% of the 
patients with glioblastoma multiforme were removed from the study before completing the 
first 8-week course of therapy because of neurological deterioration and tumor progression 
by the 5th week of treatment. CONCLUSION: This study suggests that eflornithine alone 
is an effective palliative therapy for recurrent anaplastic gliomas. Additional studies are 
needed to confirm our finding. 
TI: Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients. 
AU: Boiardi-A; Silvani-A; Milanesi-I; Broggi-G; Fariselli-L 
SO: I-Neurooncol. 1992 Feb; 12(2): 153-8 
AB: Thirty-five adult recurrent GBM patients, divided randomly in two groups of 19 and 
16 cases, had been treated with two regimens of chemotherapy: a) 
'eight -drugs-in-one-day'; b) procarbazine + CCNU + vincristine (PCV) respectively. 
Chemotherapy was planned at the tumour relapse and delivered as long as tolerated 
without irreversible sequelae or until the CT scan showed tumor progression. Multiple 
agents are used simultaneously in the therapeutic approach using 'eight-in-one' to kill as 
many heterogeneous cells of malignant glial tumor as possible and minimize the emergence 
of cellular resistance to chemotherapy. Rate response to chemotherapy and the median 
adjunctive survival time (6.5 and 6 months, respectively) are not significantly different in 
the two arms of this study. Our experience with such an aggressive multi-drugs 
combination 'eight-in-one-day' was disappointing if compared with less toxic, better 
tolerated and easy delivered (PCV) regimen. 
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